# Decision Memo for Erythropoiesis Stimulating Agents (ESAs) for non-renal disease indications (CAG-00383N)

# **Decision Summary**

Emerging safety concerns (thrombosis, cardiovascular events, tumor progression, and reduced survival) derived from clinical trials in several cancer and non-cancer populations prompted CMS to review its coverage of erythropoiesis stimulating agents (ESAs). We reviewed a large volume of scientific literature, including basic science research, to see if these safety signals seen in randomized controlled trials could be reasonably explained in whole or in part by the actions of ESAs on normal or cancerous cells. In doing so we proposed conditions of coverage based on expression of erythropoietin receptors. The scientific understanding of this mechanism is a subject of continuing debate among stakeholders, continues to evolve, and can only be resolved through additional studies. We also reviewed a large volume of comments on the use of ESAs in myelodysplastic syndrome (MDS), a pre-malignant syndrome that transforms into acute myeloid leukemia (AML) in many patients. Though we continue to be interested in these specific issues, this final decision does not differentiate ESA coverage by the erythropoietin receptor status of the underlying disease, and we have narrowed the scope of this final decision to make no national coverage determination (NCD) at this time on the use of ESAs in MDS.

CMS has determined that there is sufficient evidence to conclude that erythropoiesis stimulating agent (ESA) treatment is not reasonable and necessary for beneficiaries with certain clinical conditions, either because of a deleterious effect of the ESA on their underlying disease or because the underlying disease increases their risk of adverse effects related to ESA use. These conditions include:

- 1. any anemia in cancer or cancer treatment patients due to folate deficiency, B-12 deficiency, iron deficiency, hemolysis, bleeding, or bone marrow fibrosis;
- 2. the anemia associated with the treatment of acute and chronic myelogenous leukemias (CML, AML), or erythroid cancers;
- 3. the anemia of cancer not related to cancer treatment;
- 4. any anemia associated only with radiotherapy;
- 5. prophylactic use to prevent chemotherapy-induced anemia;
- 6. prophylactic use to reduce tumor hypoxia;
- 7. patients with erythropoietin-type resistance due to neutralizing antibodies; and
- 8. anemia due to cancer treatment if patients have uncontrolled hypertension.

We have also determined that ESA treatment for the anemia secondary to myelosuppressive anticancer chemotherapy in solid tumors, multiple myeloma, lymphoma and lymphocytic leukemia is only reasonable and necessary under the following specified conditions:

- 1. The hemoglobin level immediately prior to initiation or maintenance of ESA treatment is < 10 g/dL (or the hematocrit is < 30%).
- The starting dose for ESA treatment is the recommended FDA label starting dose, no 2. more than 150 U/kg/three times weekly for epoetin and 2.25 mcg/kg/weekly for darbepoetin alpha. Equivalent doses may be given over other approved time periods.
- Maintenance of ESA therapy is the starting dose if the hemoglobin level remains below 3. 10 g/dL (or hematocrit is < 30%) 4 weeks after initiation of therapy and the rise in hemoglobin is > 1g/dL (hematocrit > 3%).
- For patients whose hemoglobin rises <1 g/dl (hematocrit rise <3%) compared to 4. pretreatment baseline over 4 weeks of treatment and whose hemoglobin level remains <10 g/dL after the 4 weeks of treatment (or the hematocrit is <30%), the recommended FDA label starting dose may be increased once by 25%. Continued use of the drug is not reasonable and necessary if the hemoglobin rises <1 g/dl (hematocrit rise <3 %) compared to pretreatment baseline by 8 weeks of treatment.
- Continued administration of the drug is not reasonable and necessary if there is a rapid 5. rise in hemoglobin > 1 g/dl (hematocrit > 3%) over 2 weeks of treatment unless the hemoglobin remains below or subsequently falls to < 10 g/dL (or the hematocrit is < 30%). Continuation and reinstitution of ESA therapy must include a dose reduction of 25% from the previously administered dose.
- ESA treatment duration for each course of chemotherapy includes the 8 weeks 6. following the final dose of myelosuppressive chemotherapy in a chemotherapy regimen.

Local Medicare contractors may continue to make reasonable and necessary determinations on all uses of ESAs that are not determined by NCD.

Back to Top

# **Decision Memo**

TO: Administrative File: CAG #000383N

The Use of Erythropoiesis Stimulating Agents in Cancer and Related Neoplastic

**Conditions** 

FROM: Steve Phurrough, MD, MPA

Director, Coverage and Analysis Group

Louis Jacques, MD Director, Division of Items and Devices

Maria Ciccanti, RN Lead Analyst

Kimberly Long Analyst

Elizabeth Koller, MD, FACE Medical Officer

Shamiram Feinglass MD, MPH Medical Officer

SUBJECT: Coverage Decision Memorandum for the Use of Erythropoiesis Stimulating Agents in Cancer and Related Neoplastic Conditions

DATE: July 30, 2007

#### I. Decision

Emerging safety concerns (thrombosis, cardiovascular events, tumor progression, and reduced survival) derived from clinical trials in several cancer and non-cancer populations prompted CMS to review its coverage of erythropoiesis stimulating agents (ESAs). We reviewed a large volume of scientific literature, including basic science research, to see if these safety signals seen in randomized controlled trials could be reasonably explained in whole or in part by the actions of ESAs on normal or cancerous cells. In doing so we proposed conditions of coverage based on expression of erythropoietin receptors. The scientific understanding of this mechanism is a subject of continuing debate among stakeholders, continues to evolve, and can only be resolved through additional studies. We also reviewed a large volume of comments on the use of ESAs in myelodysplastic syndrome (MDS), a pre-malignant syndrome that transforms into acute myeloid leukemia (AML) in many patients. Though we continue to be interested in these specific issues, this final decision does not differentiate ESA coverage by the erythropoietin receptor status of the underlying disease, and we have narrowed the scope of this final decision to make no national coverage determination (NCD) at this time on the use of ESAs in MDS.

CMS has determined that there is sufficient evidence to conclude that erythropoiesis stimulating agent (ESA) treatment is not reasonable and necessary for beneficiaries with certain clinical conditions, either because of a deleterious effect of the ESA on their underlying disease or because the underlying disease increases their risk of adverse effects related to ESA use. These conditions include:

- 1. any anemia in cancer or cancer treatment patients due to folate deficiency, B-12 deficiency, iron deficiency, hemolysis, bleeding, or bone marrow fibrosis;
- 2. the anemia associated with the treatment of acute and chronic myelogenous leukemias (CML, AML), or erythroid cancers;
- 3. the anemia of cancer not related to cancer treatment;
- 4. any anemia associated only with radiotherapy;
- 5. prophylactic use to prevent chemotherapy-induced anemia;
- 6. prophylactic use to reduce tumor hypoxia;

- 7. patients with erythropoietin-type resistance due to neutralizing antibodies; and
- 8. anemia due to cancer treatment if patients have uncontrolled hypertension.

We have also determined that ESA treatment for the anemia secondary to myelosuppressive anticancer chemotherapy in solid tumors, multiple myeloma, lymphoma and lymphocytic leukemia is only reasonable and necessary under the following specified conditions:

- 1. The hemoglobin level immediately prior to initiation or maintenance of ESA treatment is < 10 g/dL (or the hematocrit is < 30%).
- 2. The starting dose for ESA treatment is the recommended FDA label starting dose, no more than 150 U/kg/three times weekly for epoetin and 2.25 mcg/kg/weekly for darbepoetin alpha. Equivalent doses may be given over other approved time periods.
- 3. Maintenance of ESA therapy is the starting dose if the hemoglobin level remains below 10 g/dL (or hematocrit is < 30%) 4 weeks after initiation of therapy and the rise in hemoglobin is  $\geq$  1g/dL (hematocrit  $\geq$  3%).
- 4. For patients whose hemoglobin rises <1 g/dl (hematocrit rise <3%) compared to pretreatment baseline over 4 weeks of treatment and whose hemoglobin level remains <10 g/dL after the 4 weeks of treatment (or the hematocrit is <30%), the recommended FDA label starting dose may be increased once by 25%. Continued use of the drug is not reasonable and necessary if the hemoglobin rises <1 g/dl (hematocrit rise <3 %) compared to pretreatment baseline by 8 weeks of treatment.
- 5. Continued administration of the drug is not reasonable and necessary if there is a rapid rise in hemoglobin > 1 g/dl (hematocrit > 3%) over 2 weeks of treatment unless the hemoglobin remains below or subsequently falls to < 10 g/dL (or the hematocrit is < 30%). Continuation and reinstitution of ESA therapy must include a dose reduction of 25% from the previously administered dose.
- 6. ESA treatment duration for each course of chemotherapy includes the 8 weeks following the final dose of myelosuppressive chemotherapy in a chemotherapy regimen.

Local Medicare contractors may continue to make reasonable and necessary determinations on all uses of ESAs that are not determined by NCD.

# II. Background

In this section in our proposed decision memorandum, we described the technological developments that gave rise to the use of genetically engineered (recombinant) erythropoietin and related ESAs (see appendix A). We then described the anemias for which ESAs are prescribed in oncologic conditions, with an emphasis on solid tumors that constituted the majority of tumors in the studies upon which FDA approval was based. We refer the reader to Appendix A for a detailed discussion of the biochemical background of ESAs and their current usages. We will summarize these points here.

Erythropoietin is a glycoprotein produced primarily in the kidney and to a lesser extent in the liver. In the classic hormone pathway, erythropoietin regulates erythrocyte production by stimulating red cell production in the bone marrow. Suppression of erythropoietin production or suppression of the bone marrow response to erythropoietin has resulted in anemias in several disease processes to include renal disease, cancer treatment, other chronic diseases and use of certain drugs.

To combat these anemias, several forms of recombinant human erythropoietin have been developed. The two currently available in the US are epoetin and darbepoetin alpha. Recombinant erythropoietin was initially used as a replacement for missing hormone in select patients with anemia of end-stage renal disease. Use of ESAs has been extended to a variety of anemic conditions including the anemia of chronic renal disease (not yet on dialysis), anemia secondary to chemotherapy of solid tumors, anemia secondary to AZT therapy, anemia in myelodysplastic disorders and prophylactic use during the perioperative period to reduce the need for allogenic blood transfusions.

In cancer, anemia occurs with varying degrees of frequency and severity. It is most frequent in genitourinary, gynecologic, lung, and hematologic malignancies. Anemia may be directly related to cancer type or to its treatment.

Oncologic anemia occurs by a variety of mechanisms. Poor oral intake or altered metabolism may reduce nutrients (folate, iron, vitamin B-12) essential for the red cell production. Antibodies in certain tumor types may cause increased erythrocyte destruction through hemolysis. Tumors may cause blood loss via tissue invasion, e.g. gastrointestinal bleeding from colon cancer. Other neoplasms, particularly hematologic malignancies (leukemia, lymphoma, multiple myeloma) can invade the bone marrow and disrupt the erythropoietic microenvironment. In more advanced cases, there may be marrow replacement with tumor or amyloid. Marrow dysfunction can occur, however, even in the absence of frank invasion (Faquin 1992; Mikami 1998). Inflammatory proteins from interactions between the immune system and tumor cells are thought to cause inappropriately low erythropoietin production and poor iron utilization as well as a direct suppression of red cell production.

The treatment of cancer may also cause anemia. Radical cancer surgery can result in acute blood loss. Radiotherapy and many cytotoxic chemotherapeutic agents cause marrow suppression to some degree. Damage is due to a variety of mechanisms. For example, alkylating agents cause cumulative DNA damage, anti-metabolites damage DNA indirectly, and platinum-containing agents appear to damage erythropoietin-producing renal tubule cells.

Myelodysplastic disorders are a heterogenous group of pre-leukemic diseases characterized by cytopenias due to abnormal hematopoietic differentiation and maturation. The disease may be idiopathic or secondary to chemotherapy or radiation therapy for other disease. The primary defect resides in hematopoietic stem cells. New cases exceed 10,000/year. Transformation to acute non-lymphocytic leukemia occurs in 10 to 40% of patients with idiopathic MDS. Thrombocytopenic bleeding and neutropenic infections contribute to death. Survival at 3 years is approximately 40% for those over 50 (Ma 2007). Transfusion dependence and risk for leukemic transformation appear related to disease severity/diagnostic category. Therapeutic treatment of MDS related anemia requires treatment of the underlying marrow disorder. Treatment in younger patients is allogenic bone marrow transplantation. Treatment with cytotoxic agents has demonstrated limited utility. Supportive care includes transfusions and avoidance/treatment of iron overload. Readers interested in more information may wish to review the discussion of MDS by the National Cancer Institute (NCI) at <a href="http://www.cancer.gov/cancertopics">http://www.cancer.gov/cancertopics</a>.

In opening this NCD in March of this year, CMS stated that it would be reviewing the non-ESRD uses of ESAs. In our proposed decision in May of this year, we restricted our proposal to oncologic uses of ESAs. However, as pointed out to us, MDS is not an oncologic condition. Thus, we are making no decision on MDS in this final decision.

The level at which anemia requires intervention is not well established. By tradition, patients have been transfused at the hemoglobin level of 7 or 8 g/dl to avoid symptoms and physiologic complications. A transfusion of 2 or more units would result in an increase of at least 2 g/dl of hemoglobin (6 units of hematocrit). Indeed, one of the endpoints for pharmaceutical registration, need for transfusion, employed an 8 g/dl hemoglobin cut-off (FDA Medical Officer Review, Aranesp 2002). Most of these practices, however, are based on empiric observations and not clinical trials. In one of the few studies, Carson et al. found that hip-fracture patients transfused to hemoglobin levels in excess of 10 g/dl did not have more exercise tolerance than non-transfused patients who were transfused after hemoglobin levels dropped to below 8 g/dl or patients became symptomatic (Carson 1998).

The British Blood Transfusion Society has delineated the weaknesses in our knowledge base. Their guidelines state that transfusions are indicated in patients with hemoglobin levels less than 7 g/dl and that transfusion should not be undertaken for hemoglobin levels greater than 10 g/dl. They indicate that management of patients with hemoglobin levels between 7 and 10 remains unclear although the hemoglobin threshold for the treatment of patients with co-morbid conditions is probably higher than 7 g/dl. Although they have done so in the past, the College of American Pathologists (CAP) no longer issues transfusion practice guidelines.

Other groups have developed definitions for anemia and have been cited for these definitions, but these definitions cannot be extrapolated into guidelines for oncologic treatment. The World Health Organization (WHO) definitions for anemia were developed for surveillance of anemia due to nutritional deficiency and parasitic infections. The National Cancer Institute (NCI) has information on anemia, but does not issue treatment guidelines (Robin Bason 301-594-9051; NCI anemia information from web). Both the NCI and WHO consider hemoglobin levels less than 6.5 g/dl to be life-threatening.

## **III. History of Medicare Coverage**

Prior to this National Coverage Analysis, there was no National Coverage Decision (NCD) concerning the use of ESAs for the indications discussed in this Decision Memorandum. Currently, the Medicare benefit for ESAs for end-stage renal disease (ESRD) related anemia is outlined in the Medicare Benefit Policy Manual, Chapter 11, Section 90 and Chapter 15, Section 50.5.2. For other indications, Medicare coverage of ESAs administered incident to a physician service for other indications under Part B is determined by local Medicare contractors.

Medicare is a defined benefit program. An item or service must fall within a benefit category as a prerequisite to Medicare coverage. § 1812 (Scope of Part A); § 1832 (Scope of Part B); § 1861(s) (Definition of Medical and Other Health Services). ESAs fall within the benefit categories specified in 1861(s)(2)(A) & 1861(s)(2)(B) of the Social Security Act.

#### IV. Timeline of Recent Activities

March 14, 2007	CMS opened an internally generated National Coverage Decision (NCD) to evaluate coverage of uses of ESAs in non-renal disease applications. The initial 30-day comment period opened.
April 13, 2007	The initial public comment period closed; 69 timely comments were received.
May 14, 2007	CMS published the Proposed Decision Memorandum. The 30 -day public comment period opened.

The public comment period on the proposed decision closed. 2641 timely comments were received.

#### V. FDA Status

**A.** Erythropoietin-alpha was the first ESA approved by the FDA for use in renal failure (1989). Subsequently two ESAs were approved for the management of the anemia of cancer treatment (chemotherapy) of non-myeloid neoplastic disease: epoetin (1993) and darbepoetin alpha (2002).

**B.** FDA reviewed results of the Breast Cancer Erythropoietin Trial (BEST) and Henke studies. Concerns regarding an increased rate of tumor progression and increased mortality were incorporated into the Precautions Section of product labeling in 2004.

**C.** FDA convened a meeting of the Oncologic Drugs Advisory Committee 5/4/2004 to discuss safety issue for ESAs. The briefing information and transcript for the meeting is available at www.fda.gov/ohrms/dockets/ac/cder04.html#Oncologic.

**D.** In conjunction with the FDA, Amgen issued a "Dear Doctor Letter" regarding the use of ESAs for anemia management in the absence of chemotherapy, which was sent 1/26/2007.(See www.fda.gov/medwatch/safety/2007/safety07.htm#Aranesp)

**E.** Serial FDA ALERTS regarding ESA safety information were issued: 11/16/2006, 2/16/2007, and 3/09/2007.

**F.** FDA strengthened its warning about cardiovascular and thrombotic events in a variety of populations via a BLACK BOX warning. A "black box" warning is the most serious warning placed in the labeling of a prescription medication. FDA included BLACK BOX warnings for tumor progression and decreased survival in cancer patients undergoing cancer treatment. FDA also warned that ESAs are not indicated for anemic cancer patients not undergoing treatment and that mortality is increased when ESAs are used by this population. Specific warnings on the use of ESAs included that they:

- shortened the time to tumor progression in patients with advanced head and neck cancer receiving radiation therapy when administered to target a hemoglobin of greater than 12 g/dL,
- shortened overall survival and increased deaths attributed to disease progression at 4
  months in patients with metastatic breast cancer receiving chemotherapy when
  administered to target a hemoglobin of greater than 12 g/dL,
- increased the risk of death when administered to target a hemoglobin of 12 g/dL in patients with active malignant disease receiving neither chemotherapy nor radiation therapy. ESAs are not indicated for this population.

**G.** FDA convened a meeting of the Oncologic Drugs Advisory Committee (ODAC) on May 10, 2007 to discuss updated risk information on ESAs for the indication of cancer. The ODAC transcripts were recently posted at <a href="http://www.fda.gov/ohrms/dockets/ac/cder07.htm#OncologicDrugs">http://www.fda.gov/ohrms/dockets/ac/cder07.htm#OncologicDrugs</a>.

## VI. General Methodologic Principles

When making national coverage determinations, CMS evaluates relevant clinical evidence to determine whether or not the evidence is of sufficient quality to support a finding that an item or service falling within a benefit category is reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member. Critical appraisal of the evidence enables us to determine to what degree we are confident that: 1) the specific assessment questions can be answered conclusively; and 2) the intervention will improve health outcomes for patients. An improved health outcome is one of several considerations in determining whether an item or service is reasonable and necessary.

A detailed account of the methodological principles of study design that are used to assess the relevant literature on a therapeutic or diagnostic item or service for specific conditions can be found in Appendix B. In general, features of clinical studies that improve quality and decrease bias include the selection of a clinically relevant cohort, the consistent use of a single good reference standard, the blinding of readers of the index test and reference test results.

Public comment sometimes cites the published clinical evidence and gives CMS useful information. Public comments that give information on unpublished evidence such as the results of individual practitioners or patients are less rigorous and therefore less useful for making a coverage determination. CMS uses the initial public comments to inform its proposed decision. CMS responds in detail to the public comments on a proposed decision when issuing the final decision memorandum.

#### VII. Evidence

#### 1. Introduction

We are providing a summary of the evidence that we considered during our review. CMS extensively reviewed the body of literature on the use of ESAs in its proposed decision memorandum released on May 14, 2007.

(http://www.cms.hhs.gov/mcd/viewdraftdecisionmemo.asp?id=203). We will not review that evidence again in this final decision. We refer the reader to Appendix A for a full discussion.

This section presents the agency's evaluation of the evidence considered for the assessment questions:

1. Is the evidence sufficient to conclude that erythropoiesis stimulating agent therapy affects health outcomes when used by Medicare beneficiaries with cancer and related neoplastic conditions?
2. If the answer to Question 1 is affirmative, what characteristics of the patient, the disease, or the treatment regimen reliably predict a favorable or unfavorable health outcome?
We will review each of the questions in the context of our proposed individual coverage criteria separately, respond to comments on that recommendation, discuss any new evidence, and provide our response with any proposed changes. Our responses to comments on aspects of the proposed decision other than the proposed coverage criteria are summarized in the Comment Section.
Multiple studies have raised significant safety concerns about the potential for ESAs to increase tumor progression and decrease survival in cancer patients. Although some of these were studies of ESAs used during radiotherapy or for anemia of cancerboth off-label usesthe data nonetheless raises concerns about the use of ESAs for all cancer indications to include labeled indications.
Because tumor progression has now been seen in some cancer patients, we believe that to demonstrate improved health outcomes, all ESA indications need evidence demonstrating that they do not cause tumor progression and/or decrease survival even if they might decrease transfusions or improve quality of life. In concert with our general methodologic principles (Appendix B), we believe that in most instances, this evidence can only be obtained in randomized controlled trials.

Several commenters questioned CMS' references in the proposed decision to basic science literature rather than solely to clinical trials. We emphasize that the safety signals came from randomized controlled clinical trials. Our review of other literature was to shed light on the possible underlying biological processes that may account for the trial findings. This was not a shift in CMS' stated preference for methodologically robust clinical evidence in determining whether health outcomes are affected by various technologies.

We remain concerned that a number of trials have been terminated, suspended, or otherwise not completedpossibly due to signals of harmand that the existing fund of published evidence may reflect a bias toward ESA use. Transparent public access to clinical trial datasets, as opposed to data summaries, would enhance public confidence in this body of literature.

# 2. External Technology Assessments

Please refer to the Proposed Decision Memorandum for a review of this matter. (http://www.cms.hhs.gov/mcd/viewdraftdecisionmemo.asp?id=203)

## 3. Internal Technology Assessment

Systematic reviews are based on a comprehensive search of published materials to answer a clearly defined and specific set of clinical questions. A well-defined strategy or protocol (established before the results of individual studies are known) is optimal.

CMS staff extensively searched Medline (1988 to present) for primary studies evaluating ESA therapy in cancer and related conditions. The emphasis was on studies structured to assess adverse events and mortality. CMS staff likewise searched the Cochrane collection, National Institute for Health and Clinical Excellence (UK) appraisals, and the Agency for Healthcare Research and Quality (AHRQ) library for systematic reviews and technology assessments. Systematic reviews were used to help locate some of the more obscure publications and abstracts. Preference was given to English publications.

Because much of the material remains outside the domain of the published medical literature, additional sources were used. CMS examined FDA reviews of the registration trials for epoetin and darbepoetin alpha as well as the FDA safety data for epoetin and darbepoetin alpha. CMS reviewed the transcripts and briefing documents (FDA and pharmaceutical sponsor) from the 2004 FDA Oncologic Drugs Advisory Committee (ODAC) meeting on ESA safety. CMS reviewed the FDA ESA drug safety alerts and label changes. CMS searched the National Institutes of Health (NIH) Clinical Trials.gov database for ongoing/completed trials of ESAs. CMS used internet searches to identify websites with clinical trial results, press releases for clinical trial termination, and U.S. government regulatory action. We catalogued these trials in our proposed decision (Appendix A).

Following the release of the proposed NCD on May 14, 2007, we received some additional references, primarily non-Medline publications. We also updated our search and broadened it to be more inclusive for MDS and multiple myeloma. We received over 300 additional citations as comments. Many of these addressed the blood supply, transfusion errors and erythropoietin receptors. We received many articles that duplicated items in our library. We also received numerous non-Medline abstracts. We did not receive any substantive raw data for analysis. The clinical trial tables have been updated to reflect the additional data.

Published Trials of ESA Use in Cancer

More than 100 papers or abstracts on ESA use in cancer have been published. Most studies have not been structured to assess survival, tumor progression and adverse events. Many studies enrolled patients with a variety of tumors. Others enrolled patients with a single disease, but were not stratified for tumor stage. Many studies included patients on a variety of treatment regimens. Many were not randomized, placebo-controlled trials. Many studies used another ESA as an active control. Most studies did not use fixed ESA doses, instead they titrated doses upward in poor responders without a statistical analysis that took this variability into account. Concomitant iron administration limited to patients in the ESA cohort was sometimes a confounding variable. Study endpoints were hemoglobin thresholds, changes in hemoglobin, transfusion requirements (without a priori definition), or quality of life. Frequently, the hematologic endpoint was a composite based on either a change in transfusion needs or hemoglobin level. Many studies did not declare a primary endpoint. Survival and/or tumor progression, if assessed, were secondary or add on endpoints. No studies presented a priori power calculations for patient number and study duration that would be required to demonstrate clinically significant survival differences for neoplastic diseases. No studies presented a priori methods for the assessment of tumor progression. Stratification of risk by tumor type, tumor stage, treatment modality, ESA dose, or ESA response to dose was not present in any of the studies reviewed. The additional data reviewed following the proposed decision did not change these conclusions (See Tables 2 and 3).

4. Medicare Evidence Development and Coverage Advisory Committee (MedCA)	4. Medicare E	Evidence Develo	pment and Cover	age Advisory Co	ommittee (MedCA
--	---------------	-----------------	-----------------	-----------------	-----------------

A MedCAC meeting was not convened for this issue.

#### 5. Evidence Based Guidelines

There were no additional guidelines provided to CMS during the comment period. We describe guidelines in Appendix A.

## 6. Professional Society Position Published Statements

CMS received many comments from persons affiliated with various organizations. We distinguished bona fide position statements from professional organizations in part by determining if the author was identified as the president, executive vice president, executive director or equivalent of the society and if the comment was stated to be the position of the society rather than of an individual. All of these commenters disagreed with some provision of the proposed decision. In general, all thought that the decision was too restrictive. Some questioned CMS' legal authority to make this decision. We have summarized their input in Table 4 of the appendices; the full texts of their comments are available on our website (http://www.cms.hhs.gov/mcd/viewpubliccomments.asp?nca\_id=203). All of their comments focused on one of the proposed criteria and we respond to those below where we separately review each of our proposed determinations.

## 7. Industry comments

We received comments from both marketers of ESAs in this country. They presented similar recommendations that supported the following noncovered indications in the proposed decision:

- Indication 1. Any anemia in cancer or cancer treatment patients due to folate deficiency,
   B-12 deficiency, iron deficiency, hemolysis, bleeding or bone marrow fibrosis
- Indication 3. Anemia of myeloid cancers (specifically AML/CML, not multiple myeloma)
- Indication 6. Anemia associated with radiotherapy (primary treatment)
- Indication 7. Prophylactic use to prevent chemotherapy-induced anemia (in patients who have never suffered from CIA)
- Indication 8. Prophylactic use to reduce tumor hypoxia
- Indication 9. Patients with erythropoietin-type resistance due to neutralizing antibodies
- Indication 12. Anemia due to cancer treatment if patients have uncontrolled hypertension

They did not agree with the other proposed noncovered indications:

- Indication 2. Anemia of myelodysplasia
- Indication 10. Patients with treatment regimens including anti-angiogenic drugs such as bevacizumab
- Indication 11. Patients with treatment regimens including monoclonal/polyclonal antibodies directed against the epidermal growth factor (EGF) receptor
- Indication 13. Patients with thrombotic episodes related to malignancy

Furthermore, they recommended several changes to the restrictions on the covered indications:

- The starting hemoglobin level should be 11 g/dL
- There should be no maximum dose
- For patients whose hemoglobin does not rise > 1 g/dL in the 4 weeks, two dose escalations should be allowed
- Patients with a rapid rise in hemoglobin should have a dose reduction
- ESA use should be discontinued when the hemoglobin level is 12 g/dL

We respond to these below where we separately review each of our proposed determinations.

#### 8. Public Comments

Initial comment period: 3/14/2007 - 4/13/2007

We received 70 comments during the initial public comment period. Of the public commenters who furnished this information, 37 were from providers, 5 were from caregivers, 1 was from a patient, 13 were from professional organizations, 7 were from patient advocacy groups, 1 was from a national oncology policy consulting group and 2 were from pharmaceutical companies. Two comments regarding the use of ESAs for renal disease and two related to code assignments are included in the 70; both topics are outside the scope of this NCD.

The majority of commenters requested CMS to provide coverage of ESAs for all non-renal FDA approved indications. Several commenter included studies and scientific literature with their comments.

Comment period on the proposed decision: 5/14/2007 - 6/13/2007

CMS received 2641 comments on the proposed decision. Several individual commenters submitted multiple comments; in some cases the same comment was submitted more than once by the same commenter. It appears in quite a few instances that many clinical and/or administrative support staff members from a single medical practice submitted comments. Some commenters submitted identical comments.

Most commenters did not refer to or provide any scientific or medical evidence that had not already been reviewed in the proposed decision memorandum or that could definitively answer the outstanding safety questions surrounding ESAs. However, we received a comment from Michael Henke, MD, Professor of Medicine/Radio Oncology at the University of Freiburg, Germany, the principal investigator from one of the trials that demonstrated the safety concerns. He states, "I am convinced that ESA treatment negatively affects disease control and survival of head and neck cancer patients." He further states that confirmed findings (RTOG 99 03 and DAHANCA 10) and his own research (Henke 2003) support this view. Dr. Henke indicated that comparable safety concerns can be assumed for other cancer sites as well, for example, Leyland Jones (2005) and Wright (2007) suggest breast and lung cancer.

Many commenters described their current clinical practice or current specialty guidelines. Of the physicians who commented, almost all were self-identified as hematologists and/or oncologists. CMS staff also received comments during meetings with representatives of Amgen, Ortho Biotech-Johnson & Johnson, Genentech, ASCO, US Oncology, Marti Nelson Cancer Foundation, Colorectal Cancer Coalition, and other institutions. Each organization used these meetings to emphasize their formal comments which are available online and summarized elsewhere in this document.

Almost all commenters disagreed with some provision of the proposed decision. Some commenters expressed agreement with some aspects of the proposed decision while disagreeing with other aspects. Some commenters did not express approval or disapproval. Thus, the count of commenters is a different number than the count of opinions of the commenters. Consequently, we will provide a summary of the different opinions and not the number of commenters supporting any specific opinions. Myelodysplasia was the subject of the largest number of comments about a specific clinical condition. Commenters also frequently speculated on the effect of the proposed decision on the need for transfusions and the adequacy of the blood supply to meet higher demands.

# Subjects outside of the scope of this decision

Comment

Several commenters discussed the use of ESA therapy in the setting of anemia related to kidney disease or other uses that are beyond the scope of the proposed decision.

## Response

We will not address those comments in this decision memorandum.

# Personal or family member experience Comment

Many commenters noted personal, friend, or family experience with ESA therapy. We heard from many cancer patients attesting to the benefit of ESAs regarding their quality of life. Beneficiaries submitted testimonies describing activities that were no longer difficult or impossible as a result of ESA therapy. Family members of beneficiaries receiving ESA therapy expressed concern over the costs of ESAs should CMS no long provider coverage. They expressed anger at Medicare for burdening them with the costs of ESAs. Beneficiaries and family members commented about their belief regarding the benefit and necessity of ESA therapy, adding that they would be forced to find a means to incur the costs.

### Response

CMS carefully reviewed all the concerns submitted to us. We appreciate the comments received from the beneficiaries we serve and their families. We want our beneficiaries to have access to appropriate and quality care. While personal experiences are important and helpful to the Agency in understanding the impact of its decisions, CMS generally gives greater weight to published scientific evidence.

# Lack of transparency/access regarding primary ESA data Comment

Several commenters noted that it has been difficult if not impossible to obtain access to primary data from ESA clinical trials, and that this has made it problematic to have independent analyses of these data. They voiced support for measures that would increase

CMS received a comment from Marcia Angell, MD, Senior Lecturer in Social Medicine, Harvard Medical School, Former Editor in Chief, *New England Journal of Medicine (NEJM.)* who also expressed concern regarding the lack of transparency and access of primary ESA data. She states, "Medicare should have access to all the clinical trial information that the FDA has. Currently, companies seeking marketing approval must submit to the FDA all trials, not just the positive ones, but the agency generally does not share this information without the permission of the sponsoring company. That puts the proprietary interests of drug companies ahead of the public interest. Medicare should require full disclosure from the FDA as a condition of its support."

## Response

public access to these data.

We agree with the need for greater access to these unpublished datasets.

# Blood supply and transfusion demand

#### Comment

Several commenters asked CMS to consider the effect of ESA use on the blood supply, i.e. blood available for transfusion, if the final decision resulted in more transfusions. Commenters expressed concern that shortages in the blood supply commonly exist and is a particular problem in some minority populations.

### Response

The concern about the adequacy of the nation's blood supply is not a relevant factor for consideration in this national coverage determination. Our focus is whether the use of ESA is reasonable and necessary to treat a particular illness.

#### **Financial considerations**

### Comment

Some commenters alleged that the specific provisions of the decision were prompted by CMS financial concerns. Some allege that we are trying to save money. Others suggest that the proposed decision would result in increased Medicare expenditures.

## Response

The specific provisions of the proposed decision were derived from the regimens, including doses and durations of treatment, that were studied in clinical trials. We did not consider financial implications for these issues. Whether the decision ultimately affects Medicare expenditures is not a consideration in conducting national coverage analyses.

# **Quality of life as a research outcome** *Comment*

Many professional societies suggested that quality of life (QoL) outcomes should be a sufficient research endpoint. They urged CMS to use QoL outcomes as evidence to make a reasonable and necessary determination for coverage. For example, the American Society of Hematology (ASH) submitted a list of supporting evidence that included literature pertaining to QoL as an outcome measure for patients with cancer receiving ESA therapy.

## Response

Wisloff et al. examined the impact of hemoglobin concentration on QoL scores in 745 patients with multiple myeloma. They had the following conclusion:

"When examining the effect of haemoglobin on QoL, it is essential to adjust for disease parameters and response to therapy in order not to overestimate the impact of haemoglobin on QoL. Our findings imply that uncontrolled studies on the effect of erythropoietin (EPO) in cancer patients may be making exaggerated claims for the effect of EPO on QoL" (Wisloff 2005).

We believe that there is currently insufficient evidence to postulate a QoL benefit to support ESA use. Such evidence of benefit, if one indeed exists, requires more robust research than we have reviewed to date. However, even if such evidence existed, it would need to be weighed against the new evidence suggesting tumor progression and increased mortality.

## **Pediatric populations**

## Comment

Some commenters suggested that the proposed decision would adversely effect pediatric populations.

## Response

Infants and young children with cancer or leukemia are generally not Medicare beneficiaries. Any issues peculiar to the pediatric population are not generalizable to the Medicare population at large.

#### Coding

#### Comment

We were asked to provide ICD-9 codes with the policy.

### Response

We do not provide coding instructions in NCDs. We do, however, consider coding in the instructions that are developed to direct our contractors who process claims for items and services billed to Medicare.

### CMS authority to make the NCD

#### Comment

A commenter contested CMS' authority to limit reimbursement for ESA therapy, claiming that toxicity is not relevant to decisions about medical reasonableness. Other commenters suggest that, under Section 1861(t)(2) of the Social Security Act, Medicare cannot establish coverage conditions for ESA use in the context of anticancer treatment.

# <u>Response</u>

We disagree with these comments. CMS' authority to develop and implement NCDs is clearly and unequivocally established in statute. In determining if a particular drug is reasonable and necessary, one of several considerations is whether the drug improves health outcomes. In this context, toxicity is relevant in determining if health outcomes are improved.

Section 1861(t)(1) of the Social Security Act defines the terms "drugs" and "biologicals." The statute at § 1861(t)(2) defines a subset of "drugs," those used in an anticancer chemotherapeutic regime for a medically accepted indication. ESAs may fall under either definition, depending on the use.

The definitions of drugs and biologics at § 1861(t)(1) & (t)(2) include listings in compendia. The United States Pharmacopoeia-Drug Information (USP-DI) is a compendium that lists accepted and unaccepted uses of drugs. Both epoetin and darbepoetin alpha are included in USP-DI and have listings that were changed after the FDA released its black box warning.

Prior to the changes made in March of 2007 in the USP-DI, both darbepoetin alpha and epoetin had accepted indications for the treatment of anemia in cancer patients when the anemia was due to chemotherapy. Epoetin had an off-label indication for treatment of chronic anemia associated with neoplastic diseases. Darbepoetin alpha had an unaccepted indication for treatment of anemia of cancer not due to chemotherapy.

Following the FDA black box warning, the darbepoetin alpha unaccepted indication was strengthened with additional data. The epoetin section also had additional language added that stated that epoetin improves anemia due to cancer in patients not receiving chemotherapy, but may compromise survival. Additional language in the cancer treatment section stated that epoetin has not demonstrated improvements in cancer outcomes and may compromise survival. In sum, the current US-PDI compendium listings provide unfavorable evaluations for these drugs.

Finally, we emphasize that Medicare NCDs instruct our contractors on the coverage of items or services for which claims are made. NCDs do not direct physicians regarding the provision of any particular item or service.

# ESA overuse and revision of treatment guidelines

## Comment

A commenter said in part that ESAs are overused and suggested that revised guidelines and a lower upper threshold could allow continued use of these agents in those patients who would benefit.

# Response

We agree.

Printed on 3/10/2012. Page 25 of 201

## Preserving appropriate access

#### Comment

Y-ME National Breast Cancer Organization stated that breast cancer patients should have access to medications, including ESAs if appropriate, and noted that a significant portion of breast cancer patients are Medicare beneficiaries.

### Response

We did not propose to eliminate coverage to ESA therapy for beneficiaries with breast cancer, though we did propose limitations on the dosing that would be covered by Medicare. We believe that our final decision preserves appropriate access with due attention to the serious concerns that are reflected in the FDA black box warnings, the discussions of the ODAC, and the evidence we reviewed.

### **ESAs** are equivalent

### Comment

Several commenters stated that ESAs have the same effects and should be treated similarly in this decision.

## Response

We agree.

## **Need for more clinical trials**

## Comment

Several commenters pointed out that more clinical trials are needed to answer important outstanding questions.

Response We agree.

### **ESAs** as anti-tumor therapy

#### Comment

Commenters stated that current data do not support ESA use solely to potentiate the effectiveness of anti-tumor therapy.

<u>Response</u>

We agree.

#### **CMS** and FDA

## Comment

A commenter said that FDA approved labeling indicates when treatment is "necessary." Other commenters made various comments about FDA processes.

## Response

The labeled indication for the treatment of anemia related to chemotherapy is to decrease the need for transfusions in patients who will be receiving concomitant chemotherapy. The FDA approved label does not identify a hemoglobin (or hematocrit) level at which ESA therapy may be indicated or necessary to treat anemia in patients who have cancer that is related to receiving chemotherapy. However, the FDA label does identify hemoglobin (or hematocrit) levels at which ESA therapy may be indicated, or necessary for the treatment anemia related to chronic renal failure, and for anemic patients scheduled to undergo elective, non-cardiac, nonvascular surgery. Some commenters were confused and believed that the FDA label did, in fact, identify a specific hemoglobin/hematocrit level at which ESA therapy may be indicated or necessary to treat anemia related to chemotherapy.

CMS is not changing the FDA indication for ESA therapy for cancer patients who have anemia related to chemotherapy. CMS' coverage provision is the FDA label indication and ensures that cancer beneficiaries who have anemia related to chemotherapy can avoid transfusions by receiving ESA therapy "that will gradually increase the hemoglobin (or hematocrit)concentration to the lowest level sufficient to avoid the need for transfusion", as stated in the FDA labeled Black Box Warning.

CMS and FDA are separate agencies with different statutory missions, and operate under distinct legal authorities. CMS cannot address these comments about FDA's processes. They should be addressed to FDA directly.

#### **FDA and ODAC**

#### Comment

Several commenters requested that CMS delay rendering a proposed decision until after the FDA ODAC meeting scheduled for May 11, 2007. Other commenters suggested that we defer any final decision until the FDA has responded to the ODAC recommendations. Commenters suggested that CMS review the literature and data distributed at the ODAC meeting prior to rendering the proposed decision. Others asked if we have consulted with FDA or suggested that we consult with FDA.

## Response

As stated above, CMS and FDA are separate agencies with different statutory missions, and operate under distinct legal authorities. CMS independently reviewed the evidence prior to the ODAC meeting, which was attended by CMS staff. The concerns raised and the evidence discussed at the ODAC are consistent with the body of evidence that we had already reviewed. We are encouraged that the separate and independent analyses of the FDA and CMS have raised similar serious concerns about the use of ESA treatment in patients with cancer and related neoplastic conditions. CMS' proposed decision was published after the ODAC meeting. FDA deliberations are not public and their timeline for making changes (if any are made) in the labeling for ESAs is unknown. We believe the safety concerns that we have identified in this document required CMS to act quickly to protect beneficiaries.

# Acceptable risk Comment

A number of commenters acknowledged risks associated with ESA use but said that among individual patients there will be different judgments made by patients about what risk is acceptable in light of their personal values, religious beliefs, disease severity, and other factors. They propose that patients and physicians should be allowed to make those decisions without CMS influence.

### Response

We agree that treatment decisions regarding the use of ESAs shall be made by physicians and patients, making sound judgments about the risks associated with ESA therapy. In making national coverage determinations, we review the applicable evidence and may, as appropriate, make determinations wherein Medicare coverage for certain items and services is not reasonable and necessary. Thus, in this instance, CMS is making a determination as to those circumstances under which ESA use in patients with cancer and related neoplastic conditions is or is not reasonable and necessary.

## 9. Expert Opinion

CMS received numerous responses from individuals and organizations that could be classified as "expert." Due to the large number of these comments, we will not separately include those here. We will limit discussion under this heading to a summary of the FDA Oncologic Drugs Advisory committee (ODAC).

FDA convened the ODAC on 5/10/07 to consider ESA use in cancer. Background materials are available at: fda.gov/OHRMS/DOCKETS/ac/07/briefing/2007-4301b2-02-FDA.pdf (accessed 05/25/07). The ODAC transcripts are available at fda.gov/ohrms/dockets/ac/cder07.htm#OncologicDrugs (accessed 07/03/07).

Included among the recommendations made by the ODAC to FDA are:

- further marketing authorization be contingent upon additional restriction in product labeling;
- further marketing authorization be contingent upon additional trials;
- labeling should specifically state that ESAs are not indicated for use in specific tumor types that may include breast cancer, head and neck cancer, and non small-cell lung cancer (NSCLC);
- the current evidence is insufficient to determine a lower limit different from the current level of 10 g/dl;
- the current evidence is insufficient to determine an upper limit different from the current level of 12 g/dl; and
- product labeling should recommend discontinuation of the ESA following completion of a chemotherapy regimen and re-evaluation of the degree of anemia with subsequent chemotherapy regimen.

## **VIII. CMS Analysis**

National coverage determinations (NCDs) are determinations by the Secretary with respect to whether or not a particular item or service is covered nationally under title XVIII of the Social Security Act, § 1869(f)(1)(B). In order to be covered by Medicare, an item or service must fall within one or more benefit categories contained within Part A or Part B, and must not be otherwise excluded from coverage. Moreover, with limited exceptions, the expenses incurred for items or services must be "reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member" (§ 1862(a)(1)(A)). This section presents the agency's evaluation of the evidence considered and conclusions reached for the assessment questions:

- 1. Is the evidence sufficient to conclude that erythropoiesis stimulating agent therapy affects health outcomes when used by Medicare beneficiaries with cancer and related neoplastic conditions?
- 2. If the answer to Question 1 is affirmative, what characteristics of the patient, the disease, or the treatment regimen reliably predicts a favorable or unfavorable health outcome?

As discussed above, CMS considers improved health outcomes in its reasonable and necessary determinations. Because multiple studies have demonstrated increased tumor progression and decreased survival in certain cancer patients, there may be the potential that the ESA stimulated tumor progression and increased mortality seen in these few cancers may be seen in other cancers. Thus, we believe that in order to demonstrate improved health outcomes, we need to review evidence that demonstrates that ESAs do not cause tumor progression and/or decrease survival in these other cancers even if they might decrease transfusions or improve quality of life.

Thus, in order to assess the evidence for questions 1 and 2, we consider whether the evidence is robust and demonstrates that the use of ESAs in any cancer patient decreases transfusion requirements and/or improves survival and, if so, does the evidence demonstrate that the use of ESAs does not increase tumor progression or decrease survival?

For the convenience of the reader we have organized our analysis by the coverage criteria in our proposed decision. Following a general discussion, we will in each case:

- review public comments;
- discuss any additional evidence presented during the comment period;
- annotate the FDA labeling for that criteria;
- annotate the recommendation in the United States Pharmacopoeia-Drug Information (USP-DI), a compendium that lists accepted and unaccepted uses of drugs;
- evaluate the assessment questions above (see Section VII.1);
- · respond to the comments and evidence; and
- summarize our decision.

#### **General Discussion**

In a typical setting, physiologic replacement of a missing hormone should result in normalization caused by that deficit. Indeed many, albeit not all, patients with ESRD are deficient in erythropoietin because of damage to the renal parenchyma. Their anemia is secondary to and highly responsive to low doses of ESAs. In other settings, a hormone is used at higher than physiologic levels because of hormone resistance or to supplement endogenous pathways to achieve superphysiologic or accelerated physiologic responses.

Early ESA drug development was based on the typical setting of a deficit in erythropoietin action. The endpoints in the clinical trials were reduction in the transfusion rate, quality of life, absolute hemoglobin level, and change in hemoglobin level. The hemoglobin parameters were surrogate endpoints. Because anemia portended poor clinical outcome (Dunphy 1989; Fein 1995; Obralic 1990; Oehler 1990; Reed 1994), it was hypothesized that reversal of anemia itself would improve long-term clinical status. It was presumed that the primary risk was thromboembolic vascular events, and that these were related to hemoglobin level rather than to drug dose and/or response to drug dose. As such, most of the registration trials for FDA approval were relatively small and conducted in heterogeneous patient populations with a mixture of primarily solid tumors at various stages who were undergoing treatment with a variety of regimens. (See Proposed Decision Memorandum-drug registration section (http://www.cms.hhs.gov/mcd/viewdraftdecisionmemo.asp?id=203))

At the time of initial drug approvals for cancer-treatment associated anemia, the FDA had concerns about ESA mediated tumor initiation or promotion. The FDA requested post-approval Phase IV commitments in 1993 and 2002 to explore this putative risk promotion because the registration studies were not structured to assess overall survival, cause-specific mortality, cause-specific morbidity, tumor-free survival, and tumor progression. The post approval studies permitted heterogeneous patient populations because it was presumed that the risk benefit ratio would be similar for all tumors at all stages, for all treatment modalities, and in all adult patient populations. For a listing of Phase IV commitments, see Proposed Decision Memorandum sections on terminated trials and ongoing studies (http://www.cms.hhs.gov/mcd/viewdraftdecisionmemo.asp?id=203).

In many of the terminated trials, there was a signal suggesting decreased survival. Attribution for the precise determination of mortality cause was often not done or not done rigorously. Nonetheless, results from studies that attempted to assess cancer disease-free survival or changes in locoregional tumor control, suggest that tumor progression plays a more significant role than vascular-thrombotic events in the apparent decreased survival observed with ESA use for the anemia secondary to cancer chemotherapy, an FDA approved indication. A signal for decreased survival was also observed with ESA use for the anemia of cancer (in patients not undergoing chemotherapy) and to reduce tissue hypoxia during radiation treatments, neither of which are FDA approved indications. These observations have resulted in FDA Black Box warnings, the most serious warning placed in the labeling of a prescription medication (see section III (V) F).

Tumor progression might occur via a number of avenues. Malignant cells could be transformed, or their milieu enriched. The first mechanistic pathway includes the ability of malignant cells to survive via decreased programmed cell death (apoptosis), the ability to survive through resistance to chemo/immuno/radiotherapy, increased proliferation leading to greater tumor burden, enhanced invasiveness, and improved migratory or metastatic travel capacity. Another mechanistic pathway includes decreased tissue hypoxia and increased nutrient supply via a more extensive vascular network (angiogenesis) and increased erythrocyte number.

In the absence of definitive clinical data we have reviewed significant amount of in vitro work to support the first pathway (Acs 2001, 2002, 2003; Anagnostou 1990, 1994; Arcasoy 2003, 2005; Batra 2003; D'Andrea 1989; Digicaylioglu 1995; Farrell 2004; Fraser 1989; Haroon 2003; Henke 2006, Jones 1990; Kumar 2006; Lai 2005; Lappin 2003; Masuda 1993; Mioni 1992; Ogilvie 2000; Ribatti 2003; Rossert 2005; Selzer 2000; Westenfelder 2000; Wright 2004; Winkelman 1990; Yasuda 1998, 2001, 2006). Indeed, elements of the erythrocyte receptor signaling cascade are similar to those of epidermal growth factor (EGF) receptor, a target against which immunotherapeutic agents are being developed (Wakao 1997; Zhang 2006). Locoregional progression of head-and-neck cancer was increased in patients with tumors positive for erythropoietin receptors and who were treated with erythropoietin (Henke 2006). There is a trend for such progression even in the patients with erythropoietin receptors who did not receive erythropoietin, suggesting that endogenous erythropoietin might be variable and able to impact clinical outcome (Henke 2006). Cultured cells (cervical cancer line HT100 and glioma line U87) developed resistance to ionizing radiation and cis-platinum after exposure to erythropoietin (Belenkov 2004; Yasuda 2003). Incubation with an inhibitor to the erythropoietin receptor's JAK-STAT pathway, typhostin (AG490), could reverse this resistance (Belenkov 2004).

The picture, however, is not straightforward. As such, universal statements about how ESA use results in the outcomes seen in oncology cannot be made. Erythropoietin receptor number may change with the cell cycle (Acs 2001; Broudy 1991). The number may increase with the stage of the tumor (Acs 2001). Some cell lines do not exhibit proliferation in response to erythropoietin exposure (Wesphal 2002). Indeed, Henke et al. found that locoregional progression of head-and-neck cancer was not increased in erythropoietin-treated patients lacking erythropoietin receptors (Henke 2006). Mittelmann et al. even found myeloma regression in mice after ESA treatment (Mittelmann 2001). Tovari et al. found that ESA treatment might enhance sensitivity to 5-fluorouracil chemotherapy (Tovari 2005).

There is also a significant amount of *in vitro* work that supports the second mechanistic pathway. Microvascular density and tumor stage (for neuroblastomas and hepatocellular carcinomas) have been found to correlate with both erythropoietin and erythropoietin receptor expression (Ribatti 2007 A&B). This suggests that there is tumor secretion of erythropoietin that binds to erythropoietin receptors on vasculature which, in turn, proliferates and further promotes tumor growth (Ribatti 2007 A&B). Secretion of pro-angiogenic factors and recruitment of vascular endothelium has also been observed with human mesenchymal stem cells which, like cancer cells, are less differentiated than normal cells (Zwezdaryk 2007). There has even been a report of the conversion of myelodysplastic syndrome (MDS) to leukemia attributed to erythropoietin's angiogenic effects on the bone marrow (Bunworasate 2001; Ribatti 2002). Indeed anti-angiogenic monoclonal antibody therapy has been approved for colon cancer and is under development for other tumors (Panares 2007). Nonetheless, erythropoietin-induced angiogenesis has not been found in all cancers or test models (Hardee 2005).

Oncology patients may be exposed to supraphysiologic ESA doses. Many cancer patients manifest erythropoietin resistance, i.e., they have an inappropriately low endogenous erythropoietin response to anemia (Ward 1977) and do not respond to low exogenous dose levels (Miller 1990). This is likely to be compounded in geriatric patients who are known to have reduced hematopoietic reserve (Miller 1990). Less frequent dosing regimens, although equivalent to more frequent dosing regimens on the basis of a hematologic response, result in higher peak blood levels of hormone (Chung 1998, 2001; Kryzunski 2005; Ramakrishnan 2004). It is not known whether supraphysiologic ESA blood levels would increase the likelihood of spill-over from the classic high affinity erythropoietin receptor binding sites in the bone marrow to non-marrow receptors with different binding constants where it can act as a growth factor (Fraser 1988, 1989; Masuda 1993; Hardee 2006) or whether excess hormone is bound by the soluble erythropoietin receptors secreted by some tumors (Harris 1996; Maeda 2001; Wesphal 2002).

Regardless of the cause(s), careful prospective trials controlled for the tumor, tumor stage and perhaps tumor cell cycle, cancer treatment, and perhaps endogenous systemic or paracrine/autocrine erythropoietin production and the presence of erythropoietin receptor on tumors and as soluble elements in the blood are needed to inform practitioners as to whether ESAs provide a meaningful clinical benefit for the various oncologic populations. Careful trials would also assess the effects of dose including doses in patients who exhibit a poor hematologic response to low doses as well as the effects of long-term dosing and repeated dosing.

We cannot be sure of the completeness of the evidentiary database because of the question of unpublished data. Negative studies were frequently not available as full published reports on Medline. The early termination of studies by data safety monitoring boards, investigators, and/or pharmaceutical sponsors because of a safety concern does not permit complete appraisal of the magnitude of safety risk. Early termination may reduce the statistical power of a safety finding. Nonetheless, evidence of harm is apparent despite these limitations. ESA treatment has been associated with an increased risk of thrombotic-vascular disease, tumor progression, and decreased survival. Furthermore, there are potential mechanisms that could explain the etiology of the harm.

Although the evidence is less robust than we would like, particularly for geriatric patients, it is sufficient to identify certain patient characteristics and treatment practices that have a high likelihood of unfavorable clinical outcomes. In our proposed decision, we identified several instances in which this high likelihood occurred. Additionally, we proposed that for other indications, we limit use of ESAs to tumors with erythropoietin receptors and to specific targets that we felt the evidence supported. Use of ESAs in other tumors was left to contractor discretion.

The following subsections will discuss each indication separately and any changes to what we proposed.

## **Analysis by Specific Indications**

Proposed Noncovered Indication #1: Any anemia in cancer or cancer treatment patients due to folate deficiency, B-12 deficiency, iron deficiency, hemolysis, bleeding, or bone marrow fibrosis

#### Public Comments

Commenters on this issue supported the CMS proposed decision. A majority of commenters agreed that use of ESAs for these indications was not supported by evidence. Two societies suggested that this indication be covered in the case of marrow fibrosis, but agreed with the rest of the restrictions.

#### Additional Evidence

We received no new evidence supporting the use of ESAs in the treatment of anemia in cancer patients due to the conditions listed.

We note that the current FDA labels for Epogen (epoetin) and Aranesp (darbepoetin alpha) respectively include the following relevant language.

EPOGEN (epoetin) is not indicated for the treatment of anemia in cancer patients due to other factors such as iron or folate deficiencies, hemolysis, or gastrointestinal bleeding, which should be managed appropriately.

A lack of response or failure to maintain a hemoglobin response with Aranesp (darbepoetin alpha) doses within the recommended dosing range should prompt a search for causative factors. Deficiencies of folic acid, iron or vitamin B12 should be excluded or corrected. Depending on the clinical setting, intercurrent infections, inflammatory or malignant processes, osteofibrosis cystica, occult blood loss, hemolysis, severe aluminum toxicity and bone marrow fibrosis may compromise an erythropoietic response.

We note that the USP-DI has similar language for both epoetin and darbepoetin alpha.

### Response

We agree with the majority of the commenters who supported this decision. We were not presented evidence, nor did we find any evidence that would support the use of ESAs in marrow fibrosis. We are finalizing our decision of noncoverage for this indication.

## Summary

We have determined that ESAs are not reasonable and necessary for any anemia in cancer or cancer treatment patients due to folate deficiency, B-12 deficiency, iron deficiency, hemolysis, bleeding, or bone marrow fibrosis.


## Proposed Noncovered Indication #2: Anemia of myelodysplasia (MDS)

#### **Public Comments**

Commenters on this issue strongly opposed the CMS proposed decision. Many commenters referred to current clinical practice and longitudinal experience to support the use of ESAs in MDS. Others suggested that these data could be sufficiently inferred from existing published trials. Others expressed concern that continuing this noncoverage would markedly increase the transfusion rate and exhaust the available blood supply

#### Additional Evidence

Data was presented demonstrating that MDS patients on ESAs had fewer transfusions than had been historically needed for MDS patients prior to ESAs.



# Proposed Noncovered Indications #4: Anemia associated with the treatment of myeloid cancers or erythroid cancers

#### Public Comments

Commenters were most concerned about how CMS defined myeloid cancer. They requested that multiple myeloma be specifically excluded from this definition. They supported the CMS proposed decision to noncover use in acute and chronic myelogenous leukemias (AML and CML) and erythroid cancers.

#### Additional Evidence

We received no new published evidence that supports the use of ESAs during the treatment of CML, AML, or erythroid cancers.

The FDA approved label for Epogen (epoetin) includes the following language.

EPOGEN (epoetin) is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.

Aranesp (darbepoetin alpha) is indicated for the treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis and for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.

The USP-DI has similar language for both epoetin and darbepoetin alpha.

## Response

We agree that multiple myeloma is not included in the definition of myeloid cancer. We also agree with the commenters that the noncoverage for myeloid cancers be specifically linked to CML and AML. We clearly listed it among the solid tumors for which we proposed restricted coverage.

## Summary

We will modify our proposed decision and define the specific myeloid cancers that are noncovered. We have determined that ESAs are not reasonable and necessary for any anemia associated with the treatment of CML, AML, or erythroid cancers.

## Proposed Noncovered Indication #5: Anemia of cancer not related to cancer treatment

#### Public Comments

Most commenters were in support of this noncoverage, stating that this was the setting in which much of the adverse outcomes were reported. Some commenters suggested that in spite of the evidence, physicians should make individual decisions about the use of ESAs in this setting. Some beneficiaries with cancer stated that they received ESA therapy continuously for years. Others stated that they continue to receive ESA therapy, though their cancer is in remission. Some commenters suggested Coverage with Evidence Development (CED) for this indication.

#### Additional Evidence

We received no additional published evidence supporting the use of ESAs for the treatment of anemia not related to cancer. We were provided with observational data on the improvement in QoL scores in some patients who received ESAs while not under treatment. No data supported any improvement in other measures of morbidity or survival.

FDA: This is an off-label use. We note that the labels for Epogen/Procrit (epoetin) and Aranesp (darbepoetin alpha) include the following language in their black box warnings. increased the risk of death when administered to target a hemoglobin of 12 g/dL in patients with active malignant disease receiving neither chemotherapy nor radiation therapy. ESAs are not indicated for this population. In the USP-DI, epoetin is listed under the section 'Acceptance not established' with the language: Epoetin improves anemia due to cancer in patients not receiving chemotherapy, but may compromise survival. USP-DI lists darbepoetin alpha as not indicated ("unaccepted") for the treatment of anemia associated with neoplastic diseases. Response

Use of ESAs in cancer not associated with treatment is the specific indication in which much of the reports of adverse events have occurred. While we agree that physicians and patients have the freedom to make independent treatment choices, this Agency must evaluate the relevant evidence and make determinations to ensure that Medicare coverage is provided only for items and services that are reasonable and necessary. In this case, we have determined that the use of ESAs for this indication is not reasonable and necessary. Moreover, this determination is supported by the strong FDA black box warning.

CMS uses coverage with evidence development when we believe there is some evidence of benefit but not to the point of national coverage. In this case, there is evidence of harm and thus we do not believe that CED is appropriate for ESA use for this indication.

### Summary

The evidence we reviewed and the public comments support the determination that ESAs are not reasonable and necessary for any anemia in cancer that is not related to cancer treatment.

## Proposed Noncovered Indication #6: Anemia associated with radiotherapy

### **Public Comments**

The majority of commenters on this issue supported the CMS proposed decision. Those few that disagreed noted that in some cases (especially colorectal cancer) chemotherapy is given in concert with radiotherapy. They did not disagree with radiotherapy alone as being a limitation to coverage.

#### Additional Evidence


We received no additional evidence supporting the use of ESAs in the treatment of anemia associated with radiotherapy.

FDA: This is an off label use. We note that the labels for Epogen/Procrit (epoetin) and Aranesp (darbepoetin alpha) include the following language in their black box warnings.

 shortened the time to tumor progression in patients with advanced head and neck cancer receiving radiation therapy when administered to target a hemoglobin of greater than 12 g/dL.

The USP-DI has strong warnings for the use of ESAs for this indication.

Printed on 3/10/2012. Page 42 of 201



# Proposed Indication #7: Prophylactic use to prevent chemotherapy-induced anemia Public Comments The majority of commenters on this issue supported the CMS proposed decision. A few commenters did advocate for prophylactic use in patients who were about to receive chemotherapy. Additional Evidence We received no additional evidence supporting the use of ESAs to prevent chemotherapyinduced anemia. FDA: This is an off-label use. USP-DI: This indication is not listed nor discussed in the USP-DI for epoetin or darbepoetin alpha. Response Given the evidence surrounding this and the public comments on this issue, this indication will remain non-covered.


The evidence reviewed and the comments received support the determination that ESAs are not reasonable and necessary for prophylactic use to prevent anemia in beneficiaries who

## Printed on 3/10/2012. Page 44 of 201

Summary

have cancer.

Proposed Noncovered Indication #8: Prophylactic use to reduce tumor hypoxia
Public Comments All commenters on this issue supported the CMS proposed decision.
Additional Evidence We received no additional evidence supporting the use of ESAs to reduce tumor hypoxia.
FDA: This is an off-label use.
The USP-DI does not address this indication.
Response We agree with the public comments received regarding this proposed decision.
Summary The evidence reviewed and the comments received support the determination that ESAs are not reasonable and necessary for prophylactic use to reduce tumor hypoxia.



The USP-DI does not address erythropoietin resistance due to neutralizing antibodies.

## Response

We recognize that this is not a commonly performed test. However, there is broad evidence to indicate that the use of ESAs in patients who, for any reason, have had this test performed with a positive result, may lead to negative outcomes. Given the favorable comments and the fact that we received no new evidence, this indication will remain noncovered.

## Summary

The evidence reviewed and the comments received support the continuing determination that ESAs are not reasonable and necessary in beneficiaries with erythropoietin-type resistance due to neutralizing antibodies.

Proposed Noncovered Indication #10: Patients with treatment regimens including antiangiogenic drugs such as bevacizumab

#### Public Comments

Commenters on this issue generally opposed the CMS proposed decision restricting the use of ESAs in patients receiving anti-angiogenic drugs. Commenters also contested our assumptions about the angiogenic effects of ESAs. Several commenters have noted that concomitant use with anti-angiogenic therapy is contraindicated. Several commenters noted that many chemotherapy drugs have some anti-angiogenic properties. Also, commenters suggested that the concern about the interaction of ESAs with anti-angiogenic drugs are only theoretical and have not been demonstrated in practice. Many supported CED in lieu of noncoverage when anti-angiogenic drugs are used alone. A manufacturer of an anti-angiogenic drug expressed concern that a specific drug was cited as an example, rather than referring to the class of drugs alone.

#### Additional Evidence

Published data evaluating the addition of ESAs to chemotherapy regimens including antiangiogenic drugs were not available. One company presented an analysis of data from trials involving bevacizumab. In that analysis it separately evaluated outcomes on patients receiving ESAs and those not receiving ESAs and found no differences in outcomes.

Printed on 3/10/2012. Page 47 of 201

FDA: This is a labeled indication.

The USP-DI does not list nor include any indication/discussion regarding treatment regimens including anti-angiogenic drugs for either epoetin or darbepoetin alpha.

## Response

Angiogenesis appears to be important for both tumor growth and metastasis formation. Until neoplasms acquire the potential to induce vessel formation that can ensure adequate nutrition and oxygen, their growth is effectively held in check. Targeting angiogenesis is more focused than generalized cytotoxic or cytostatic therapy which targets all rapidly growing cells (Seimann 2005). Anti-angiogenesis can be achieved in several ways. Repeated small doses of chemotherapy can be given to semi-selectively poison the vascular epithelium (metronomic therapy). Other drugs do this by targeting growth factors (e.g. basic fibroblast growth factor [bFGF], platelet derive growth factor [PDGF], transforming growth factor [TGF], and vascular endothelial growth factor [VEGF]), their receptors, matrix metalloproteinases, and tumor suppressor gene activity (Bouis 2006; Svensson 2003; Zhong 2006).


Hardee et al. have provided some of the most compelling data for angiogenesis. Breast cancer cells injected into a window chamber imbedded in living mice showed evidence of vessel formation (angiogenesis) and tumor size progression that was greater than controls when the cells were exposed to erythropoietin (Hardee 2007). These changes occurred in the absence of differences in hematocrit levels. These findings could be blunted by any one of three inhibitors: recombinant soluble erythropoietin receptor, neutralizing monoclonal erythropoietin antibody, or mutant erythropoietin (competitive inhibition). There were similar findings of vessel proliferation and tumor progression, when breast cancer cells were genetically altered to include a mutant and constitutively active (always on) erythropoietin receptor. The findings from the window chamber assay were replicated in an assay using the mouse mammary fat pad.

Folkman has stated that the benefits of anti-angiogenic therapy might be limited by the redundancy or multiplicity of pathways for angiogenesis (Folkman 2006). Vascular endothelial growth factor (VEGF) is not the sole regulator of angiogenesis. Farrell and Lee state "...Ribatti and colleagues recently provided evidence that erythropoietin can also elicit an angiogenic response in endothelial cells in vitro and in vivo, and, thus, like VEGF, is an effective angiogenic factor...In agreement with the previous studies in human umbilical vein endothelial cells and bovine adrenal capillary endothelial cells, recombinant human erythropoietin substantially increased EA.hy926 cell proliferation. Furthermore, recombinant human erythropoietin exposure resulted in a three-fold greater matrix metalloproteinase 2 activity in treated EA.hy926 cultures compared with cell cultures grown in untreated media" (Farrell 2004). The first author of this paper is a Johnson & Johnson scientist.

It is not known whether the anti-angiogenic activity (efficacy) of these drugs are significantly diminished by the angiogenic activity of ESAs since prospective drug interaction studies have not been done. For the same reason, it is also not known whether 1) the cardiovascular complications, fluid retention, thrombosis, and hypertension observed with the anti-angiogenic monoclonal antibody, bevacizumab, are unique to the drug or are class effect and 2) the likelihood of these adverse effects, which also occur with ESAs, would be increased by combination use (Dear Doctor Letter with FDA warning 2004, 2006; USA Today 8/13/04). As we are modifying our proposed decision, CED is not an option.

## Summary

Some evidence supports the pathophysiologic construct that ESAs can stimulate certain growth factors (VEGF, EGFR) that are the targets of chemotherapy. The appropriate evidence would be randomized trials that evaluate the addition of ESAs to standard treatment regimens. That evidence is not available. We have strongly considered, as many commenters suggested, whether this indication would be appropriate for CED. However, CED restricts coverage to within research studies. Coverage would not be available to any patients outside the study. We have considered options that would enroll beneficiaries initially into observational studies that could be used to assist in designing the appropriate randomized trial. However, the complexities of this option exceed the Agency's current ability to manage those vastly differing studies. In addition, as some of the data presented indicated, some patients do appear to have an improved QoL with appropriate ESA dosing. Thus, we will remove the proposed noncoverage from the final decision. However, since the tumor types for which these drugs are indicated are included below, the use of ESAs with these agents must meet the restrictions outlined below.



The recognition of the epidermal growth factor receptor (EGFR) as an oncogene has resulted in the development of pharmacologic agents directed against the growth factor or its receptor. These agents have numerous targets including the external domain of the receptor, phosphorylation sites, and the DNA itself (anti-sense gene therapy) (Lai 2007; Paez 2004). These agents include cetuximab, erlotinib, gefitinib, and panitumumab. The signaling cascades for the epidermal growth factor and erythropoietin receptors are complex, but appear to have some overlap in pathways or targets (Oda 2005; Witthun 1993). For example, STAT-3 activation appears to occur with both (Grandis 1998; Kirito 2002). This overlap suggests that the efficacy of anti-EGFR therapy could be diminished by concomitant ESA use. Definitive answers are not available as prospective drug interaction studies have not been performed. The recent termination of the PAACE trial which assessed chemotherapy with avastin +/- panitumumab for decreased survival and pulmonary thrombosis in the experimental treatment arm suggests that these interactions cannot be predicted (Amgen press release).

### Summary

Some evidence supports the pathophysiologic construct that ESAs can stimulate certain growth factors (VEGF, EGFR) that are the targets of chemotherapy. The appropriate evidence would be randomized trials that evaluate the addition of ESAs to standard treatment regimens. That evidence is not available. We have strongly considered, as many commenters suggested, whether this indication would be appropriate for CED. However, CED restricts coverage to within research studies. Coverage would not be available to any patients outside the study. We have considered options that would enroll beneficiaries initially into observational studies that could be used to assist in designing the appropriate randomized trial. However, the complexities of this option exceed the Agency's current ability to manage those vastly differing studies. In addition, as some of the data presented indicated, some patients do appear to have an improved QoL with appropriate ESA dosing. Thus, we will remove the proposed noncoverage from the final decision. However, since the tumor types for which these drugs are indicated are included below, the use of ESAs with these agents must meet the restrictions outlined below.

Proposed Noncovered Indication #12: Anemia due to cancer treatment if patients have uncontrolled hypertension

Public Comments

All commenters on this issue supported the CMS proposed decision.

#### Additional Evidence

We received no additional evidence supporting the use of ESAs in cancer patients with uncontrolled hypertension.

FDA: Uncontrolled hypertension is a contraindicated use in both the Epogen (epoetin) and Aranesp (darbepoetin alpha) labels. We also note the following language in the labeling for Aranesp (darbepoetin alpha).

Patients with uncontrolled hypertension should not be treated with Aranesp (darbepoetin alpha); blood pressure should be controlled adequately before initiation of therapy. Blood pressure may rise during treatment of anemia with Aranesp (darbepoetin alpha) or epoetin. In Aranesp (darbepoetin alpha) clinical trials, approximately 40% of patients with chronic renal failure (CRF) required initiation or intensification of antihypertensive therapy during the early phase of treatment when the hemoglobin was increasing. Hypertensive encephalopathy and seizures have been observed in patients with CRF treated with Aranesp (darbepoetin alpha) or epoetin.

The USP-DI has similar language.

## Response

Hypertension is a well-recognized complication of ESA therapy. Patients with uncontrolled hypertension are at greater risk of complications. The FDA label specifically lists this as a contraindication for ESA therapy.

## Summary

The evidence reviewed and the comments received support the determination that ESAs are not reasonable and necessary in beneficiaries with cancer who have uncontrolled hypertension.

## Proposed Noncovered Indication #13: Patients with thrombotic episodes related to malignancy

#### **Public Comments**

Some commenters agreed with CMS. However, some commenters suggested that with proper evaluation, certain patients might be successfully placed on ESAs and an anticoagulant and managed. Commenters noted that clinical guidelines include precautions about thrombotic adverse effects. Also, commenters expressed concern that there are many other potential causes of thrombotic events in cancer patients that may not be related to the malignancy.

#### Additional Evidence

We received no additional evidence on the use of ESAs in cancer patients with thrombotic episodes.

The FDA approved labeling for both Aranesp (darbepoetin alpha) and Procrit/Epogen (epoetin) lists the following:

## Thrombotic and Cardiovascular Events

Overall, the incidence of thrombotic events was 6.2% for Aranesp (darbepoetin alpha) and 4.1% for placebo. However, the following events were reported more frequently in Aranesp (darbepoetin alpha) -treated patients than in placebo controls: pulmonary embolism, thromboembolism, thrombosis, and thrombophlebitis (deep and/or superficial). In addition, edema of any type was more frequently reported in Aranesp (darbepoetin alpha)-treated patients (21%) than in patients who received placebo (10%).

## Increased Mortality, Serious Cardiovascular and Thromboembolic Events

EPOGEN (epoetin) and other erythropoiesis-stimulating agents (ESAs) increased the risk for death and for serious cardiovascular events in controlled clinical trials when administered to target a hemoglobin of greater than 12 g/dL. There was an increased risk of serious arterial and venous thromboembolic events, including myocardial infarction, stroke, congestive heart failure, and hemodialysis graft occlusion. A rate of hemoglobin rise of greater than 1 g/dL over 2 weeks may also contribute to these risks.

To reduce cardiovascular risks, use the lowest dose of EPOGEN (epoetin) that will gradually increase the hemoglobin concentration to a level sufficient to avoid the need for red blood cell (RBC) transfusion. The hemoglobin concentration should not exceed 12 g/dL, the rate of hemoglobin increase should not exceed 1 g/d L in any two week period (see DOSAGE AND ADMINISTRATION).

The USP-DI has similar language.

## Response

We remain concerned that ESAs may precipitate lethal thrombosis. However, thrombotic events may be unrelated to the episode of chemotherapy and unrelated to the use of ESAs. While we remain concerned about this potential adverse event, commenters clearly outlined the various regimens that are available to physicians in treating these episodes. Since it will not be clear in many cases that ESAs are the causative factor in thrombotic events, we are removing this restriction in coverage.

## Summary

We have not included this proposed limitation in the final decision.

## B. Indications covered with restrictions in proposed decision

## Receptor Status in patients with cancer undergoing chemotherapy:

CMS proposed to use ESA receptor status of tumors as a selection criterion for those tumors that were more likely to have an adverse response to ESAs. While the data are preliminary, we believe that they do provide a plausible explanation for the tumor progression seen in the two trials.

#### **Public Comments**

Some commenters debated the relevance, the clinical significance, or even the existence of erythropoietin receptors on malignant or normal cells, and stated that CMS should not develop coverage criteria that are based on the putative role of these receptors in the development or progression of cancer or related conditions. Others criticized the currently available assays as being nonspecific. Others said that CMS should not extrapolate from basic science or *in vitro* studies in its discussion of a possible mechanism for the adverse outcomes associated with ESAs.

#### Additional Evidence

We have received no evidence or proposal for an alternative explanation for the tumor progression.

The FDA label and the USP-DI do not address the use of erythropoietin receptor status as a criterion for determining use of ESAs.

## Response

We are aware that there is spirited discussion about erythropoietin receptors. We proposed a mechanism to explain the cancer progression that has been seen with the use of ESAs in clinical trials and which has been highlighted in the black box warning. Though various commenters have objected to our proposal, they have not offered alternative explanations.

The presence of erythropoietin receptors on nonmalignant cells does not exclude an effect of ESAs on malignant cells at physiologic or supraphysiologic levels. Similarly, erythropoietin may exert additional effects beyond its usual physiologic pathway.

Farrell and Lee have stated, "Given the potentially wide range of functions of erythropoietin and the erythropoietin receptor, the mechanisms underlying these functions must be determined. Interestingly, Lappin and colleagues, repeating some work done by Acs et al. found that erythropoietin receptors were present in tumor cells, but absent from surrounding normal breast tissue (Maxwell, unpublished data). This, Lappin noted, is significant because it suggests the potential use of erythropoietin receptors of a tumor to target an erythropoietin-attached drug to the tumor and not damage the surrounding healthy tissue (Farrell 2004).

Indeed, it is possible that erythropoietin as a ligand may be interacting with cells through other receptors as well as erythropoietin receptors. Regardless of the route, evidence of a biologic effect after exposure is paramount. Although some of the *in vitro* data are conflicting (Rosti 1993), these contradictions might be explained by the cell lines or tissues that were used. Erythropoietin might have its most important effects in certain tissue subsets. Indeed, Phillips et al. have recently shown that the stem cells that reside within a tissue are such an important subset (Phillips 2007). Breast cancer initiating cell (stem cells) exposed to erythropoietin increased both their population size and capacity for self-renewal.

## Summary

We agree with the commenters on the lack of maturity of this data. However, in response to the commenters we will not use this distinction in the final policy. We will consider all solid tumor types, multiple myeloma, lymphoma, and lymphocytic leukemia, regardless of ESA receptor status, to fall under the restrictions defined below.

## **Proposed Restrictions**

1. The hemoglobin/hematocrit levels immediately prior to initiation of dosing for the month should be < 9 g/dl (hematocrit < 27%) in patients without known cardiovascular disease and < 10 g/dl/30% in patients with documented symptomatic ischemic disease that cannot be treated with blood. (We suggest that patients, especially those in the latter category, be alerted to the increased potential for thrombosis and sequelae.)

#### Public Comments

Many commenters stated that CMS arbitrarily selected the proposed maximum hemoglobin level at which ESA therapy could be initiated. Those who opposed this restriction suggested higher levels. ASH suggested that instead of identifying a hemoglobin level when ESA therapy is covered by Medicare, CMS should identify a level when the physician should evaluate the possible need for ESA therapy. Others commented that ESAs should be considered when the hemoglobin drops below 11 g/dL and should be stopped at a hemoglobin of 12 g/dL (hematocrit of 36%).

#### Additional Evidence

We received no additional published information regarding the threshold for intervention for transfusions/ESAs, the timing of anemia onset with chemotherapy and the rate of anemia onset with chemotherapy. Per Dr. Henry Chang, National Institutes of Health/National Heart/Lung Institute/Extramural (NIH-NHLBI-Extramural), there is a large on-going study that may address transfusion thresholds, albeit in a perioperative population.

The FDA label states that ESAs are indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. ESAs are indicated to decrease the need for transfusions in patients who will be receiving chemotherapy. The dose should be titrated for each patient to achieve and maintain the lowest hemoglobin level sufficient to avoid the need for blood transfusion and not to exceed 12 g/dL. Prior to the Black Box warning, some labels included a suggested hemoglobin target range of 10 -12 g/dL.

The USP-DI lists the treatment of anemia in adults with nonmyeloid malignancies in which the anemia is due to the effect of concomitantly administered chemotherapy in order to decrease the need for transfusion as an accepted indication. The General Dosing section includes the following language, "To reduce cardiovascular and thromboembolic risks, the lowest dose of epoetin alfa should be used. The dose administered should gradually increase the hemoglobin concentration to the lowest level sufficient to avoid the need for red blood cell transfusion. The hemoglobin concentration should not exceed 12 g per dL. However, in the Dose Adjustment/Therapeutic Goal section, the following language is included, "The dosage of epoetin must be individualized to maintain the hemoglobin within the suggested target range, 10 to 12 g per dL. At the physician's discretion, the suggested target hemoglobin range may be expanded to achieve maximal patient benefit."

For darbepoetin alpha, the following language is in 'General Dosing Information.'

To reduce cardiovascular risks, the lowest dose of darbepoetin alpha should be used. The dose administered should gradually increase the hemoglobin concentration to the lowest level sufficient to avoid the need for red blood cell transfusion. The hemoglobin concentration should not exceed 12g/dL.

ASCO and ASH guidelines recommended evaluating patients for the need for ESA therapy when the hemoglobin is at or below 10 g/dL.

## Response

The current label for ESAs indicates that there is increased risk for death and serious cardiovascular events when the hemoglobin is greater than 12g/dL. The label does not identify a specific hemoglobin level for treatment initiation or treatment target in patients with anemia induced by chemotherapy. The goal is to avoid transfusions. Transfusions are not required for hemoglobin levels 10.0g/dL or greater. There are no definitive data regarding transfusion need, and by extension ESA need for patients with hemoglobin levels between 7 and 10 g/dL. We proposed that patients who have hemoglobin levels less than 9g/dL are potential candidates for initiation or continuation of ESA therapy. Many commenters recommended that we raise that to 11g/dL.

Removal of the hemoglobin target range of 10-12 g/dl indicates that treatment of chemotherapy induced anemia should no longer focus on keeping the hemoglobin above 10 g/dL but at the lowest level that will prevent transfusions while still remaining below 12 g/dL. Although transfusion guidelines no longer provide hemoglobin initiation levels, it is a common practice for physicians to only transfuse patients when the hemoglobin approaches or drops below 8 g/dL. Thus, use of ESAs should begin at a hemoglobin level most likely to prevent the hemoglobin from dropping to 8 g/dL.

The ODAC did not identify specific a hemoglobin target at which ESA therapy should begin, but recommended that FDA establish one.

We proposed that initiating ESAs at a hemoglobin of 9 g/dL would be a sufficient starting point to prevent transfusions. The commenters disagreed and recommended 11 g/dL but with the outcome of keeping the hemoglobin above 10 g/dL. They argued that ESAs may take several weeks to reach peak activity and that if not started earlier, the hemoglobin was likely to drop to transfusion levels. Evidence to support that was lacking.

## Summary

Because changes in hemoglobin after chemotherapy do not appear to be precipitous and because a response to ESAs can be seen as early as 2 weeks, we do not believe that early intervention at a hemoglobin of 11 g/dL with ESAs is reasonable and necessary (Barrett-Lee 2000, 2006; Birgegard 2005, 2006, 2007; Coiffier 2001; Tas 2002). However, we do agree that a starting level of 9 g/dL has the potential to result in more hemoglobins dropping to transfusion levels and will thus modify our proposed decision and find that the use of ESAs is reasonable and necessary in beneficiaries with cancer undergoing myelosuppressive therapy when their hemoglobin levels immediately prior to initiation or maintenance of ESA treatment are < 10 g/dL (or the hematocrit < 30%).

## 2. The maximum covered treatment duration is 12 weeks/year.

#### Comment

Many commenters disagreed with the proposed overall 12-week limit on ESA coverage and noted that many chemotherapeutic regimens are longer than 12 weeks. Several commenters supported ESA therapy for 4 weeks to 12 weeks after cessation of myelosuppressive chemotherapy. Still others supported ongoing ESA therapy that could last for years. A commenter asked us to clarify the timeframe to distinguish anemia resulting from chemotherapy from anemia due to other causes. Some commenters suggested specific timeframes, such as six weeks, 90 days, and one year. Others were unclear if this meant a total of 12 weeks/year of 12 weeks after completion of chemotherapy.

#### Additional Evidence

No additional published data regarding the duration of anemia after myelosuppressive chemotherapy and the cessation of such therapies was presented except for studies describing residual post therapy tissue platinum levels (Stewart 1982, 1994; Tothill 1992; Vermorkem 1986). No additional substantive data discriminating between the anemia due to chemotherapy after cessation of therapy and the anemia of cancer were provided.

FDA and USP-DI do not address maximum doses in its recommended dosing.

## Response

Our intent for this restriction was not clearly understood. The controlled segments of the registration trials were 12-16 weeks long. We do not have substantive information for longer treatment cycles and for repeat treatment cycles. There are limited data on the temporal aspects of marrow recovery and the duration of anemia after myelosuppressive chemotherapy (Barrett-Lee 2000, 2006; Birgegard 2005, 2006, 2007; Coiffier 2001; Tas 2002). The ODAC voted overwhelmingly (16-1) against the continuation of ESA therapy after the completion of chemotherapy, but did not define the time period beyond which persisting anemia could no longer be attributed to the chemotherapy. The public comments were varied. Thus, we have modified our initial proposal and have determined that treatment of anemia due to myelosuppressive chemotherapy is reasonable and necessary up to 8 weeks following the last dose of myelosuppressive chemotherapy.

## Summary

We have determined that continued use of ESAs for beneficiaries with cancer whose anemia is related to chemotherapy is not reasonable and necessary after 8 weeks following the final dose of myelosuppressive chemotherapy in a chemotherapy regimen. There are no restrictions on chemotherapy regimen frequency or duration in this decision.
3. The maximum covered 4 week treatment dose is 126,000 units for erythropoietin and 630 µg for darbepoetin alpha.
Public Comments  Commenters on this topic generally opposed the maximum doses that we proposed. A commenter supported the implementation of maximum ESA dosage ranges, with the possibility for individual case consideration as an exception. Many felt that the other restrictions imposed would limit the overall dose. Some commented that the maximums were not therapeutically equal for the two drugs. Many recommended that we specify the starting and maintenance dose and not have a maximum dose. They questioned why CMS would impose dose limitations when the drug label does not.
Additional Evidence  No additional published information regarding the long term safety in cancer and cancer related conditions were provided. No additional published information comparing long term safety of ESAs for those who responded to low doses versus those who required high doses for any hemoglobin response versus non responders was provided.
The current FDA labels and USP-DI recommend a starting dose of 150U/kg/three times weekly for epoetin and 2.25 mcg/kg/week for darbepoetin alpha.
Response

We agree with the commenters that a fixed maximum covered dose may interfere with appropriate patient management. Labeled dosing is based upon weight and thus maximum doses will vary by weight. Although fixed dose studies have been conducted by the sponsors, are discussed in FDA labeling, and reported to be therapeutically equivalent, most of the labeled dosing is based on weight. Also, a more important issue is to begin at the lowest dose necessary to prevent transfusion. Thus, we will not continue with a fixed maximum dose limitation as imposed in the proposed decision, recognizing that the clinically appropriate number may vary with the beneficiary's weight and response to therapy. However, we will apply a limitation to the starting dose as indicated by the label. For epoetin, the recommended starting dose is no more than 150U/kg/TIW. For darbepoetin alpha, the recommended starting dose is no more than 2.25 mcg/kg/week. Maintenance of these doses may continue if the hemoglobin level has not risen about the initiation level of 10 g/dL (hematocrit 30%) 4 weeks after the initiation of treatment and the hemoglobin rise is  $\geq$  1 g/dL (hematocrit  $\geq$  3%).

## Summary

We have determined that the starting dose for ESA treatment is the recommended FDA label starting dose, no more than 150 U/kg/three times weekly for epoetin and 2.25 mcg/kg/weekly for darbepoetin alpha. Equivalent doses may be given over other approved time periods. Maintenance of ESA therapy is the starting dose if the hemoglobin level remains below 10 g/dL (or hematocrit is < 30%) 4 weeks after initiation of therapy and the rise in hemoglobin is  $\geq 1g/dL$  (hematocrit  $\geq 3\%$ ).

4. Continued use of the drug is not reasonable and necessary if there is evidence of poor drug response (hemoglobin/hematocrit rise <1 g/dl/<3%) after 4 weeks of treatment.

#### Public Comment

Many commenters stated that non-response should result in the administration of a higher dose. Most recommended that at least one dose escalation be allowed to better identify non-responders. ASH suggested that ESAs should not be continued after eight weeks in the absence of response, assuming the appropriate dose increase has been attempted in low-responders. US Oncology supported discontinuation after six weeks if the hemoglobin did not rise 1 g/dl or greater. All commenters supported discontinuation of ESA therapy in the face of non-response. A few commenters proposed that no change in the hemoglobin level after ESA therapy was initiated, that is, no increase or decrease, should be accepted as evidence of response to ESA therapy.

#### Additional Evidence

No groups supplied published data on safety outcomes in poor responders. The change in transfusion need for poor responders after ESA dose increases is not well characterized because of the use of composite endpoints and the lack of stratification by response.


The FDA label recommends that epoetin be increased to 300U/kg/TIW if there is no rise in hemoglobin after 8 weeks. The label recommends that darbepoetin alpha dose be adjusted to prevent transfusions and keep Hgb < 12 g/dL.

Dosing recommendations listed in the USP-DI are confusing, and at times, contradictory. Under the "Three Times a Week Dosing," it states, "If response is not satisfactory (no reduction in transfusion requirements or no rise in hemoglobin after 8 weeks), increase dose to 300 Units per kg of body weight three times a week to achieve the suggested target hemoglobin range, 10 to 12 g per dL. And, the 'Weekly Dosing' section states, "If after 4 weeks of therapy, the hemoglobin has not increased by 1 g per dL, in the absence of RBC transfusion, the epoetin dose should be increased to 60,000 Units weekly. If the patient has not responded after 4 weeks of additional therapy at 60,000 Units weekly, it is unlikely the patient will respond to higher doses of epoetin".

We note the following language in 'General Dosing Information (usual adult dose, anemia associated with chemotherapy in cancer patients)'

For patients receiving weekly administration, if there is less than a 1g/dL increase in hemoglobin after 6 weeks of therapy, the dose of darbepoetin alpha should be increased up to 4.5 mcg/kg of body weight.

## Response



## Summary

We have determined that it is reasonable and necessary to increase the covered dose once by 25% in patients whose hemoglobin rise is < 1 g/dl (hematocrit rise < 3%) compared to pretreatment baseline over 4 weeks of treatment and the hemoglobin level has remained < 10 g/dL (hematocrit < 30%) after the 4 weeks of treatment. Continued use of the drug is not reasonable and necessary if the hemoglobin rise is < 1 g/dl (hematocrit rise <3 %) compared to pretreatment baseline after 8 weeks of treatment.

5. Continued administration of the drug is not reasonable and necessary if there is an increase in fluid retention or weight (5 kg) after 2 weeks of treatment.

#### **Public Comments**

We had very few commenters addressing this specific proposal. Of those who did, some commenters opposed this restriction citing lack of clinical evidence. Another comment suggested this be clarified to distinguish between fluid retention or weight gain not associated with cancer.

### Additional Evidence

No additional data were submitted. The FDA approved labeling for both Aranesp (darbepoetin alpha) and Procrit/Epogen (epoetin) respectively reflect these concerns.

## Thrombotic and Cardiovascular Events

Overall, the incidence of thrombotic events was 6.2% for Aranesp (darbepoetin alpha) and 4.1% for placebo. However, the following events were reported more frequently in Aranesp (darbepoetin alpha)-treated patients than in placebo controls: pulmonary embolism, thromboembolism, thrombosis, and thrombophlebitis (deep and/or superficial). In addition, edema of any type was more frequently reported in Aranesp (darbepoetin alpha)-treated patients (21%) than in patients who received placebo (10%).

## Increased Mortality, Serious Cardiovascular and Thromboembolic Events

EPOGEN (epoetin) and other erythropoiesis-stimulating agents (ESAs) increased the risk for death and for serious cardiovascular events in controlled clinical trials when administered to target a hemoglobin of greater than 12 g/dL. There was an increased risk of serious arterial and venous thromboembolic events, including myocardial infarction, stroke, congestive heart failure, and hemodialysis graft occlusion. A rate of hemoglobin rise of greater than 1 g/dL over 2 weeks may also contribute to these risks.

To reduce cardiovascular risks, use the lowest dose of EPOGEN (epoetin) that will gradually increase the hemoglobin concentration to a level sufficient to avoid the need for RBC transfusion. The hemoglobin concentration should not exceed 12 g/dL, the rate of hemoglobin increase should not exceed 1 g/d L in any two week period (see DOSAGE AND ADMINISTRATION).

The USP-DI has similar language.

## Response

We remain concerned that ESAs may precipitate edema and heart failure. However, weight changes in cancer patents may have a multitude of causes. As discussed above in thrombotic events, it is typically not clear to practitioners that edema and heart failure would be due to the ESA versus other causes. Thus, we will not continue this restriction.

## Summary

We are not including this proposed limitation in the final decision.

Printed on 3/10/2012. Page 65 of 201

6. Continued administration of the drug is not reasonable and necessary if there is a rapid rise in hemoglobin/hematocrit >1 g/dl/>3% after 2 weeks of treatment.
Public Comments Some public commenters suggested that the ESA dose be lowered rather than discontinuing ESA therapy. Others suggested that there was not enough clinical evidence to allow CMS to make this decision. Commenters cited the FDA label to decrease the dose, not discontinue ESA therapy.
Additional Evidence No additional substantive published data were provided.
The FDA approved labeling as well as the USP-DI dosing recommendation for EPOGEN/Procrit (epoetin) and Aranesp (darbepoetin alpha) include the following:
If the hemoglobin increases by more than 1.0 g/dL in a 2-week period, the dose should be decreased by approximately 25%.
Response In several clinical trials, patients with brisk hemoglobin responses were excluded from further dosing and follow-up. Brisk hemoglobin response has been linked to thrombosis.

We have determined that continued administration of the drug is not reasonable and necessary if there is a rapid rise in hemoglobin > 1 g/dl (hematocrit > 3%) in 2 weeks of treatment unless the hemoglobin remains below or subsequently falls to < 10 g/dL (or the hematocrit is < 30%) and there has been a dose reduction of 25% from the previously administered dose.

## **Summary of restrictions for covered indications:**

For patients with anemia secondary to anticancer chemotherapy, ESAs are appropriate when the hemoglobin is < 10g/dL (hematocrit < 30%). The maximum dose for the first 4 weeks is 1800 U/kg for epoetin and 9 mcg/kg for darbepoetin alpha. If after the first 4 weeks the hemoglobin is > 10g/dL (hematocrit > 30%), ESA treatment is not covered. ESA treatment may resume if the hemoglobin again drops below 10g/dL (hematocrit below 30%). If after any 4 week ESA treatment cycle, the hemoglobin remains below 10 g/dL (hematocrit below 30%), ESA treatment may continue at the same dose. If after the first 4 week ESA treatment cycle, the hemoglobin rise is less than 1 g/dL (hematocrit < 3%) and the hemoglobin level remains < 10 g/dL (hematocrit < 30%), the dose may be increased by 25% one time. If the rise in hemoglobin is < 1g/dL (hematocrit < 3%) for 8 weeks in spite of a 25% increase in dose, ESA treatment should be discontinued. If after any 2 week period of time, the hemoglobin rise is > 1g/dL (hematocrit > 3%), then ESA treatment should be discontinued unless the hemoglobin is < 10 g/dL (hematocrit <3 0%) at which time ESA treatment may be reinstituted at a dose reduction of 25%. ESA treatment meeting the above requirements may be continued for 8 weeks following the completion of the final dose of myelosuppressive chemotherapy in a chemotherapy regimen.

## IX. Conclusion

Emerging safety concerns (thrombosis, cardiovascular events, tumor progression, and reduced survival) derived from clinical trials in several cancer and non-cancer populations prompted CMS to review its coverage of erythropoiesis stimulating agents (ESAs). We reviewed a large volume of scientific literature, including basic science research, to see if these safety signals seen in randomized controlled trials could be reasonably explained in whole or in part by the actions of ESAs on normal or cancerous cells. In doing so we proposed conditions of coverage based on expression of erythropoietin receptors. The scientific understanding of this mechanism is a subject of continuing debate among stakeholders, continues to evolve, and can only be resolved through additional studies. We also reviewed a large volume of comments on the use of ESAs in myelodysplastic syndrome (MDS), a premalignant syndrome that transforms into acute myeloid leukemia (AML) in many patients. Though we continue to be interested in these specific issues, this final decision does not differentiate ESA coverage by the erythropoietin receptor status of the underlying disease, and we have narrowed the scope of this final decision to make no NCD at this time on the use of ESAs in MDS.

CMS has determined that there is sufficient evidence to conclude that erythropoiesis stimulating agent (ESA) treatment is not reasonable and necessary for beneficiaries with certain clinical conditions, either because of a deleterious effect of the ESA on their underlying disease or because the underlying disease increases their risk of adverse effects related to ESA use. These conditions include:

- 1. any anemia in cancer or cancer treatment patients due to folate deficiency, B-12 deficiency, iron deficiency, hemolysis, bleeding, or bone marrow fibrosis;
- 2. the anemia associated with the treatment of acute and chronic myelogenous leukemias (CML, AML), or erythroid cancers;
- 3. the anemia of cancer not related to cancer treatment;
- 4. any anemia associated only with radiotherapy;
- 5. prophylactic use to prevent chemotherapy-induced anemia;
- 6. prophylactic use to reduce tumor hypoxia;
- 7. patients with erythropoietin-type resistance due to neutralizing antibodies; and
- 8. anemia due to cancer treatment if patients have uncontrolled hypertension.

We have also determined that ESA treatment for anemia secondary to myelosuppressive anticancer chemotherapy in solid tumors, multiple myeloma, lymphoma and lymphocytic leukemia is only reasonable and necessary under the following specified conditions:

- 1. The hemoglobin level immediately prior to initiation or maintenance of ESA treatment is < 10 g/dL (or the hematocrit is < 30%).
- 2. The starting dose for ESA treatment is the recommended FDA label starting dose, no more than 150 U/kg/three times weekly for epoetin and 2.25 mcg/kg/weekly for darbepoetin alpha. Equivalent doses may be given over other approved time periods.
- 3. Maintenance of ESA therapy is the starting dose if the hemoglobin level remains below 10 g/dL (or hematocrit is < 30%) 4 weeks after initiation of therapy and the rise in hemoglobin is  $\geq$  1g/dL (hematocrit  $\geq$  3%).
- 4. For patients whose hemoglobin rises < 1 g/dl (hematocrit rise < 3%) compared to pretreatment baseline over 4 weeks of treatment and whose hemoglobin level remains < 10 g/dL after the 4 weeks of treatment (or the hematocrit is < 30%), the recommended FDA label starting dose may be increased once by 25%. Continued use of the drug is not reasonable and necessary if the hemoglobin rises < 1 g/dl (hematocrit rise < 3 %) compared to pretreatment baseline by 8 weeks of treatment.
- 5. Continued administration of the drug is not reasonable and necessary if there is a rapid rise in hemoglobin > 1 g/dl (hematocrit > 3%) over 2 weeks of treatment unless the hemoglobin remains below or subsequently falls to < 10 g/dL (or the hematocrit is < 30%). Continuation and reinstitution of ESA therapy must include a dose reduction of 25% from the previously administered dose.
- 6. ESA treatment duration for each course of chemotherapy includes the 8 weeks following the final dose of myelosuppressive chemotherapy in a chemotherapy regimen.

Local Medicare contractors may continue to make reasonable and necessary determinations on all uses of ESAs that are not determined by NCD.


**Appendices** [PDF, 4MB] Back to Top


## **Bibliography**


Abbrederis K, Bassermann F, Schuhmacher C, Voelter V, Busch R, Roethling N, Siewert JR, Peschel C, Lordick F. Erythropoietin-alfa during neoadjuvant platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: results of a phase II trial. 2006 Gastrointestinal Cancers Symposium:44.

Abels R. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Seminars in Oncology. 1992;19 (No 3 Suppl 8):29-35.

Abel R. Erythropoietin for anaemia in cancer patients. Eur J Cancer. 1993;29A(Suppl 2):S2-8
Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001;61:3561–5.
Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer. 2002;95:969–81.
Acs G, Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol. 2003;162:1789–806.
Adamson JW, Ludwig H. Predicting the hematopoietic response to recombinant human erythropoietin (epoetin alfa) in the treatment of the anemia of cancer. Oncology. 1999;56:46-53.
Akizawa T, Kinugasa E, Kitaoka T, Koshikawa S. Effects of recombinant human erythropoietin and correction of anemia on platelet function in hemodialysis patients. Nephron. 1991;58:400–6.
Albertsson M. Assessment of quality of life and hemoglobin values in breast-cancer patients treated with epoetin beta. Proc Am Soc Clin Oncol. 2002;21:1981.







Arcasoy M, Harris KW, Forget BG. A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation. Exp Hematol. 1999;27(1):63-74.

Arcasoy M, Jiang X, Haroon Z. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun. 2003;307:999–1007.

Arcasoy M, Amin K, Chou S-C, Haroon Z, Varia M, Raleigh JA. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res. 2005;11:20-27.

Arslan M, Kurt E, Evrensel T, Gonullu G, Demiray M, Kanat O, Manavoglu O. Efficacy of different usage strategies of recombinant human erythropoietin (rHuEPO) in platinum containing chemotherapy. Proc Am Soc Clin Oncol;2002;21:2884.

Arslan M, Evrensel T, Kurt E, Demiray M, Gonullu G, Kanat O, Manavoglu O. Comparison of clinical outcomes of different erythropoietin usage strategies. Tumori. 2004;90:394-8.

AuBuchon JP. Managing change to improve transfusion safety. Transfusion. 2004;44:1377-83.

Auerbach M, Ballard H, Trout J, McIlwain M, Ackerman A, Bahrain H. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multi-center, open-labeled, randomized trial. Journal of Clinical Oncology. 2004;22:1301-07.

Ault P, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Cortes JE. Use of darbepoetin alfa for the treatment of anemia occurring during imatinib therapy for CML: preliminary evidence of safety and efficacy. Proc Am Soc Clin Oncol. 2003;22:2467.

Ayash LJ, Elias A, Hunt M, Demetri G, Wheeler C, Tepler I, Schwartz G, Mazanet R, Reich E, McCauley M, Antman K, Anderson KC. Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. British Journal of Haematology. 1994;87:153-61.

Aziz K, Hashem T, Mobarek N, Bary N, Ghoneimy I, Haddad S. Does recombinant human erythropoietin improve the outcome of radiation in head and neck cancer patients? Proceedings of American Society for Therapeutic Radiology And Oncology (ASTRO). 2001;vol.unknown:#2274.

Balleari E, Gatti A, Mareni C, Massa G, Marmont A M, Ghio R.. Recombinant Human Erythropoietin for Long-Term Treatment of Anemia in Paroxysmal Nocturnal Hemoglobinuria. Haematologica 1996; 81:143-147.

Balleari E, Mareni C, Marmont AM, Ghio R. Therapy with recombinant erythropoietin in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1996;94(2):424.

Balleari E, Rossi E, Clavio M, Congiu A, Gobbi M, Grosso M, Secondo V, Spriano M, Timitilli S, Ghio R. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Annals of Hematology. 2006; 85:174-80.

Baltz B, Gregory SA, Ehmann WC, Williams D. Initial dosing of epoetin alfa 60,000 U QW followed by Q2W maintenance for anemic patients with cancer receiving chemotherapy. Journal of Clinical Oncology. 2004;22(14S):8212.

Bamias A, Aravantinos G, Kalofonos C, Timotheadou N, Siafaka V, Vlahou I, Janinis D, Pectasides D, Pavlidis N, Fountzilas G. Prevention of anemia in patients with solid tumors receiving platinum based chemotherapy by recombinant human erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology. 2003;64:102-10.

Barber D, D'Andrea D. Erythropoietin and interleukin-2 activate distinct JAK kinase family members. Mol Cell Biol. 1994;14:6506-14.

Barber D, Corless C, Xia K, Roberts T, D'Andrea D. Erythropoietin activates Raf1 by an Shc-independent pathway in CTLL-EPO-R cells. Blood. 1997;89:55-64.

Barbone FP, Middleton SA, Johnson DL, McMahon FJ, Tullai J, Gruninger RH, Schilling AE, Jolliffe LK, Mulcahy LS. Mutagenesis studies of the human erythropoietin receptor. The Journal of Biological Chemistry. 1997;272(8):4985-92.




Baron F, Frere P, Fillet G, Bequin Y. Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion. British Journal of Haematology. 20003;123:103-5.


Baron F, Frere P, Fillet G, Beguin Y. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment. Clinical Cancer Research. 2003;9:5566-72.

Barrett-Lee P, Bailey N, O'Brien M, Wager E. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer. 2000;82:93-7.

Barrett-Lee P, Ludwig H, Birgegård G, Bokemeyer C, Gascón P, Kosmidis P, Kongable G, Krzakowski M, Schneider M, Schrijvers D, Van Belle S for the European Cancer Anaemia Survey Advisory Board and Participating Centers. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology. 2006;70:34-48.

Barrios M, Alliot C. IgA multiple myeloma responding to erythropoietin monotherapy. Am J Hematol. 2005 Oct;80(2):165-6.






Belenkov A, Shenouda G, Rizhevskaya E, et al. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther. 2004;3:1525-32.

Bennett CL, Nathan DP, Adams JR. Epoetin alfa use for cancer patients in the United States and Europe: review of vignette and clinical data. Proc Am Soc Clin Oncol. 2002;21:1026.

Bennett CL, Luminari S, Nissenson AR, Klinge SA, McWilliams N, McKoy J, Raisch DW, Kim B, Casadevall N, Tallman MS. Re-importation of pharmaceuticals may be unsafe: lessons learned from the RADAR assessment of erythropoietin (EPO)-associated pure red cell aplasia (PRCA). Journal of Clinical Oncology. 2004:22(14S):2512.

Bennett CL, Cournoyer D, Carson KR, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on adverse drug events and reports (RADAR) project. Blood. 2006;106(10):3343-7.

Bergsagel DE, Phil D, Fitzgerald B, Quirt I, Meharchand J, Hasselback R. Treatment of anemia associated with multiple myeloma[Letter to the editor]. The New England Journal of Medicine. 1991;324(1):62.



Bernell P, Stenke L, Wallvik J, Hippe E, Hast R. A sequential erythropoietin and gm-csf schedule offers clinical benefits in the treatment of anaemia in myelodsyplastic syndromes. Leukemia Research. 1996;20(8):693-9.

Besa EC, Kunselman S, Nowell PC. A pilot trial of 13-cis-retinoic acid and alpha-tocopherol with recombinant human erythropoietin in myelodysplastic syndrome patients with progressive or transfusion-dependent anemias. Leukemia Research. 1998; 22:741-9.

Bessho M, Jinnai I, Matsude A, Saito M, Hirashima K. Improvement of Anemia by Recombinant Erythropoietin in Patients with Myelodysplastic Syndromes and Aplastic Anemia. International Journal of Cell Cloning. 1990; 8:445-458.

Bessho M, Jinnai I, Hirashima K, Saito M, Murohashi I, Ino H, Tsuji M, Fukuda M, Maruyama M, Kusumoto S, Tominaga K, Matsuda A, Kawai N, Itoh K, Sakata T, Handa A, Endo K, Toyoda A, Kobayashi Y, Kashimura T, Kawano N, Minanihisamatsu M. Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia. Stem Cells. 1994;12:604-15.

Bessho M, Hirashima K, Asano S, Ikeda Y, Ogawa N, Tomonaga M, Toyama K, Nakahata T, Nomura T, Mizoguchi H, Yoshida Y, Niitsu Y, Kohgo Y and the Multicenter Study Group. Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. European Journal of Haematology. 1997;58:265-72.

Bick R. Cancer-associated thrombosis. N Engl J Med. 2003;349:109-11.
Bindi M, Montemaggi M, Sabatino M, Paolelli L, Morelli R, Piazza D, Cigno A, Carreca I. Reticulocytes can represent and early indicator of the erythropoietic response to darbepoietin alfa in the anemia by chemotherapy. Journal of Clinical Oncology. 2004;22:14S #8245.
Birgegård G, Pere Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma:findings of the European Cancer Anaemia Survey. Eur J Haematol. 2006;77:378–86.
Birgegård G, Aapro M, Bokemeyer C, Dicato M, Drings P, Hornedo J, Krzakowski M, Ludwig H, Pecorelli S, Schmoll H, Schneider M, Schrijvers D, Shasha D, Van Belle S. Cancer-related anemia: pathogenesis, prevalence, and treatment. Oncology. 2005;68 (Suppl 1):3-11.
Bittorf T, Buchse T, Sasse T. Activation of the transcription factor NF-kappa B by the erythropoietin receptor:structural requirements and biological significance. Cell Signal. 2001;13:673-681.
Blau AC. Erythropoietin in Cancer: Presumption of Innocence? Stem Cells. 2007;10:1-5.
Blayney D, Fesen M, Mirtsching B, Katz D, Tomita D. Every-2-week darbepoetin alfa improves hemoglobin in anemic patients with cancer undergoing chemotherapy: a stratified analysis by tumor type. Blood. 2003;102 Issue 11. Unknown page.


Blayney DW, Spiridonidis H, Fesen MR, McGuire WP, Bhatia AW, Hellman RM, Terry D, Tomita D. Darbepoetin alfa every 2 weeks to treat chemotherapy-induced anemia: experience in a randomized, open-label study. Proc Am Soc Clin Oncol. 2003;22:3003.

Blohmer JU, Wurschmidt F, Petry U, Weise G, Sehouli J, Kimmig R. 6<sup>th</sup> interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study: sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for pts with high-risk cervical cancer. Proc Am Soc Clin Oncol. 2003;22:1798.

Blohmer J, Wuerschmidt J, Petry K, Weise G, Sehouli J, Kimming R, Dressler P, Kentenich H, Kohls A. Results with sequential adjuvant chemo-radiotherapy with vs without epoietin for patients with high-risk cervical cancer: results of a prospective, randomized, open and controlled AGO and NOGGO-intergroup study. Annals of Oncology. 2004;15 (Suppl 3):Page Unknown.

Blohmer JU, Dunst J, Harrison L, Johnston P, Khayat D, Ludwig H, O'Brien M, Van Belle S, Vaupel P. Cancer-related anemia: biological findings, clinical implications and impact on quality of life. Oncology. 2005;68(suppl 1):12-21.

Blue Cross and Blue Shield Association Technology Evaluation Center (EPC)-Chicago, IL. Seidenfeld J, Piper M, Bohlius J, Weingart O, Trelle S, Engert A, Skoetz N, Schwarzer G, Wilson J, Brunskill S, Hyde C, Bonnell C, Ziegler KM, Aronson N. Comparative effectiveness review number 3. Comparative effectiveness of epoetin and darbepoetin for managing anemia in cancer patients undergoing cancer treatments. Contract No. 290-02-0026. (www.effectivehealthcare.ahrq.gov. Accessed 4/4/07. Copies of the executive summary available via phone call (800) 358-9295 or e-mail ahrqpubs@ahrq.hhs.gov.)



Boccia R, Malik I, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy induced anemia. The Oncologist. 2006;11:409-17.


Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. Journal of the National Cancer Institute. 2005;97(7):489-98.


Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin-an updated overview. Nature Clinical Practice Oncology. 2006;3:152-64.

Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, Hyde C, Engert A. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708-14.

Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwartzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Brunskill S, Djulbegovic B, Langensiepen S, Hyde S, Engert E. Erythropoietin or darbepoetin for patients with cancer: Review. Cochrane Library. John Wiley and Sons. 2007;1-228. www.thecochranelibrary.com

Boissel J, Lee W, Presnell SR, Cohen FE, Bunn HF. Erythropoietin structure-function relationships. The Journal of Biological Chemistry. 1993;268(21):15983-93.





Bosi A, Vannucchi AM, Grossi A, Guidi S, Saccardi R, Rafanelli D, Longo G, Ferrini PR. Inadequate erythropoietin production in allogeneic bone marrow transplant patients. Haematologica. 1991;76:280-4.

Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney International. 2005;67:2346-53.


Bowen D, Hyslop A, Keenan N, Groves M, Culligan D, Johnson P, Shaw A, Geddes F, Evans P, Porter J, Cavill I. Predicting erythroid response to recombinant erythropoietin plus granulocytes colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia. Haematologica. 2006;91:5:709-10.

Boyle P, Robertson C, Kerr DJ. Anemia and neutropenia in cancer patients receiving chemotherapy. Journal of Clinical Oncology. 2004;22(14S):9706.

Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, Henze C, Löffler D, Koczan D, Thiesen HJ, Burger R, Gramatzki M, Horn F. Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood. 2004 Jan 1;103(1):242-51. Epub 2003 Sep 11.

Broudy V, Lin N, Brice M, Nakmoto B, Papayannopoulou T. Erythropoietin receptor characteristics on primary human erythroid cells. Blood. 1991;77:2583-90.





Carlisle R, Hind D, McCabe C, Jones R, Ryan A. Norcom commissioning policy on recombinant human erythropoietin for the treatment of anaemia in people with multiple myeloma and myelodysplastic syndromes. 2004.

Carson J, Terrin M, Barton F, Aaron R, Greenburg A, Heck D, Magazinger J, Merlino F, Bunce G, McClelland B, Duff A, Noveck H. A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion. 1998;38:522-9.

Casadevall N, Belanger C, Goy A, Varet B, Lang J, Poisson D. High-dose recombinant human erythropoietin administered intravenously for the treatment of anaemia in myelodysplastic syndromes. Acta Haematologica. 1992;87(suppl 1):25-7.

Casadevall N. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplantation. 2003;18(suppl 8):viii37-41.

Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarre'MC, Damai G, Giraudier S, Guerci A, Laurent G, Dombret H, Chomienne C, Ribrag V, Stamatoullas A, Marie JP, Vekhoff A, Maloisel F, Navarro R, Dreyfus F, Fenaux P, for the group Myelodysplasies F. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood. 2004;104:(2):321-27.

Cascinu S, Fedeli A, Del Ferro E, Fedeli S, Catalano G. Recombinant human erythropoietin treatment in cisplatin associated anemia: a randomized double blind trial with placebo. Journal of Clinical Oncology. 1994;12(5):1058-62.

Case D, Carey R, Fishkin E, Henry D, Jacobson R, Jones S, Keller A, Craig I, Salmotl R, Silver R, Storniolo AM, Wampler GL, Doole-i CM, Larholt KM, Nelson RA, Abels R. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. Journal of the National Cancer Institute. 1993;85(10):801-06.


Case AS, Rocconi RP, Barnes MN, Kilgore LC. Comparison of transfusion rates between erythropoietic stimulating agents in gynecologic oncology patients with chemotherapy induced anemia. Journal of Clinical Oncology. 2005;23(16S):5092.


Cazzola M, Ponchio L, Beguin Y, Rosti V, Bergamaschi G, Liberato NL, Fregoni V, Nalli G, Barosi G, Ascari E. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood. 1992;79(1):29-37.


Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Zie L, Essers U, Greil R, Grossi A, Jager G, LeMevel A, Najan A, Silingardi V, Spriano M, van Hoof A, Ehmer B. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-hodgkin's lymphoma: dose finding and identification of predictors of response. Blood. 1995;86(12):4446-53.


Cazzola M, Ponchio L, Pedrotti C, Farina G, Cerani P, Lucotti C, Novella A, Rovati A, Bergamaschi G, Beguin Y. Prediction of Response to Recombinant Human Erythropoietin (rHuEpo) in Anemia of Malignancy. Haemotolgica. 1996;81-434-41.












Printed on 3/10/2012. Page 92 of 201




Cortesi E, Gascon P, Henry D, Littlewood T, Milroy R, Pronzato P, Reinhardt U, Shasha D, Thatcher N, Wilkinson P. Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life. Oncology. 2005;68(suppl 1):22-32.


Cortesi E, Ricci S, Ucci G, Cruciani G, de Marinis F, Orecchia S. Randomized phase III study comparing standard TIW and weekly dosage of epoetin alfa with 2 weeks loading dose: preliminary results. Journal of Clinical Oncology. 2005;23(16S):8215.

Crawford J, Blackwell S, Shoemaker D, Pupa M, Sparrow T, Herndon J, Winer E, Flynn J, Dempsey H. Prevention of chemotherapy-related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-CSF support. Lung Cancer. 1997;18(1):205.

Crawford J, Blackwell S. Erythropoietin and the management of anemia in patients with lung cancer. Cancer Control Journal (supplement);5(2).


Crawford J, Robert F, Perry M, Belani C, Sarokhan B. Epoetin alfa 40,000 U once weekly maintains hemoglobin in advanced non-small cell lung cancer patients receiving first-line chemotherapy. Proc Am Soc Clin Oncol. 2003;22:628.










Printed on 3/10/2012. Page 96 of 201










Printed on 3/10/2012. Page 100 of 201



Eastern Oncology Group. www.ecog.org/general/perf\_stat.html. Accessed 4/13/07.

Eckardt K, Ratcliffe P, Tan C, Bauer C, Kurtz A. Age-dependent expression of the erythropoietin gene in rat liver and kidneys. J Clin Invest. 1992;89:753–60.

Eckardt K, Kurtz A. Regulation of erythropoietin production. Eur J Clin Invest. 2005;35(Suppl. 3):13–9.

Economopoulos T, Mellou S, Papageorgiou E, Pappa V, Kokkinou V, Stathopoulou E, Pappa M, Raptis S. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin. Leukemia. 1999;13:1009-12.


Edwards R, Rickles F, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J Lab Clin Med. 1981;98:917-28.


Elandt K, Horak P, Schieder KC, Leikermoser R, Altmann R, Albrecht A, Reisenberger K, Tomek S, Fischer H, Zielinski CC, Krainer M. Early vs. late treatment with darbepoetin alfa in patients with genitourinary tumors during chemotherapy. Journal of Clinical Oncology. 2006;24(18S):18583.


Elbert B, Bunn H. Regulation of the erythropoietin gene. Blood. 1999;94:1864-77.


El-Rayes BF , LoRusso PM. Targeting the Epidermal growth Factor Receptor. British Journal of Cancer. 2004;91:418-424.


Printed on 3/10/2012. Page 102 of 201











Printed on 3/10/2012. Page 107 of 201

Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. The Prostate. 2006;66:135-45.


Finelli EV, Bosi C, El-Cheikh J, Martinelli G, Malagola M, Rondoni M, Baccarani M. High doses of recombinant erythropoietin alfa for myelodysplastic syndromes: high incidence of responses in patients with low pre-treatment serum erythropoietin concentrations. Journal of Clinical Oncology. 2004;22(14S):6683.

Fischl M, Galpin J, Levine J, Groopman J, Henry D, Kennedy P, Miles S, Robbins W, Starrett B, Zalusky R. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med. 1990;322:1488-93.

Fisher B, Redmond C, Legault-Poisson S, Dimitrov V, Brown M, Wickerham D, Wolmark N, Margolese R, Bowman D, Glass A. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990;8:1005-18.

Fraser J, Lin F, Berridge M. Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line, Exp Hematol. 1988;16:836-42.

Fraser J, Tan A, Lin F, Berridge M. Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes. Exp Hematol. 1989;17:10-6.




Frolove A, Schuller K, Tzeng CD, Cannon EE, et al. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol Ther. 2007 Apr 13;6(4). PMID: 17457047.

Fujisaka Y, Tamura T, Ohe Y, Kunitoh H, Sekine I, et al. Pharmacokinetics and pharmacodynamics of weekly epoetin chemotherapy-induced anemia. Journal of Clinical Oncology. 2004;22(15S): 8206.

Fujisaka Y, Tamura T, Ohe Y, Kunitoh H, Sekine I, Yamamoto N, Nokihara H, Horiike A, Kodama T, Saijo N. Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients. J Clin Oncol. 2006;36(8):477-82.

Gabrilove J, Cleeland C, Livingston R, Sarokhan B, Winer E, Einhorn L. Clinical evaluation of once weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three times weekly dosing. J Clin Oncol. 2001;19(11):2875-82.


Gabrilove JL, Cleeland C, Perez E, Mendes E, Tomita D, Colowick A. Assessment of symptom burden using the MD Anderson Symptom Inventory (MDASI) in subjects with nonmyeloid malignancies receiving multicycle chemotherapy and darbepoetin alfa every two weeks (Q2W). Proc Am Soc Clin Oncol. 2003;22:3161.




Ganser A, Hoelzer D. Clinical use of hematopoietic growth factors in the myelodysplastic

Printed on 3/10/2012. Page 110 of 201

syndromes. Seminars in Hematology. 1996;33(3):186-95.





Glaspy J, Jadeja J, Justice G, Darbepoetin alfa 2000174 Study Group, Fleishman A, Armstrong S, Colowick A. Optimizing the management of anemia in patients with cancer: a randomized, active-controlled study investigating the dosing of darbepoetin alfa. Proc Am Soc Clin Oncol. 2002;21:1446.

Glaspy J, Tchekmedyian NS, Erder MH, Isitt J, Kallich J. Early and sustained improvement in health-related quality of life (HRQOL) was observed with frontloaded darbepoetin alfa compared to conventional therapy. Proc Am Soc Clin Oncol. 2003;22:3063.

Glaspy J, Berg R, Tomita D, Rossi G, Vadhan-Raj S. Final results of a phase 3, randomized, open-label study of darbepoetin alfa 200 mcg every 2 weeks (Q2W) versus epoetin alfa 40,000 U weekly (QW) in patients with chemotherapy-induced anemia (CIA). Journal of Clinical Oncology. 2005 ASCO Annual Meeting Proceedings, 23(16S):8125.

Glaspy J, Henry D, Canon J, Lam H, Lillie T. Darbepoetin alfa administered at varying intervals compared with weekly epoetin alfa for treating chemotherapy-induced anemia: a pooled analysis of 20 clinical trials. Journal of Clinical Oncology. 2006;24(18S):18508.

Glaser C, Millesi W, Wanschitz F, Schull B, Lang S, Leitha T. R-Hu Erythropoeitin treatment increases efficacy of neo-adjuvant radiochemotherapy and improves cancer free survival of patient with oral squamous cell carcinoma: a 17 months follow-up. 1999 ASCO Annual Meeting:abstract #1543.

Glaser C, Millesi W, Kornek G, Lang S, Schull B, Watzinger, Christoph F, Lang S, Selzer E, Lavey R. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of pre-operative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharyyx. Int J Rad Oncol Biol Physics. 2001;50:705-15.


Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyion S, Vadhan-Raj S for the Procrit Study Group. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Journal of Clinical Oncology. 1997;15:1218-34.

Glaspy J, Singh J, Justice G, Kessler J, Richards D, Schwartzberg L, Rigas J, Kuter D, Harmon D, Prow D, Demetri G, Gordon D, Arseneau J, Saven A, Hynes H, Boccia R, O'Byrne J, Colowick A. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. British Journal of Cancer. 2001;84 (1):17–23.


Glaspy J, Degos L, Dicato M, Demetri G. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. The Oncologist. 2002;7:126-35.


Glaspy J, Jadeja J, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian N, Armstrong S, O'Byrne J, Rossi G, Colowick A. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. British Journal of Cancer. 2002;87:268-76.

Glaspy J, Jadeja J, Justice G, Fleishman A, Rossi G, Colowick A. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer. 2003;97 (5):1312-20.









Grossi A, Fabbri A, Santini V, Leoni F, Nozzoli C, Longo G, Pagliai G, Ciolli S, Ferrini PR. Amifostine in the treatment of low-risk myelodysplastic syndromes. Haematologica. 2000;85:367-71.


Grote T, Yeilding A, Castillo R, Fishkin E, Henry D, DeLeo M, Fink K, Sullivan D. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2005;23:9377-86.


Grudeva-Popova J. Cancer and venous thromboembolism. J BUON. 2005;10:483-9.


Gulbrandsen WF, Hjorth N, Lenhoff M, Fayers SP. Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. Eur J Haematol. 2005;75:293-8.

Gussetis ES, Peristeri J, Kitra V, Liakopoulou T, Kattamis A, Graphakos S. Clinical value of bone marrow cultures in childhood pure red cell aplasia. Journal of Pediatric Hematology/Oncology. 1998; 20(2):120-124.

Haematoloica. Editorial, comments & news. 2003;88(06):601-5.







Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amado RG. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. Journal of Clinical Oncology. 2005;23:6941-8

Heit JA, O'Fallon M, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton III J. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med. 2002;162:1245-8.

Hellstrom-Lindberg E, Birgegard G, Lockner D, Helmers C, Ost A, Wide L. Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Eur J Haematol. 1991;47:355-60.

Hellstrom-Lindberg E, Birgegard G, Carlsson M, Carneskog J, Dahl I, Dybedal I, Grimfors G, Merk K, Tangen J, Winqvist I, Ost A. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leukemia and Lymphoma. 1993;11:221-8.

Hellstorn-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a metaanalysis of 205 patients from 17 studies. British Journal of Haematology. 1995;89:67-71. Hellström-Lindberg E, Kanter-Lewensohn L, Öst A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-csf and erythropoietin. Leukemia Research. 1997;21:415-425.


Hellstrom-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, Ost A, Greenberg P. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive mode. British Journal of Haematology. 1997;99:344-51.

Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl I, Dybedal I, Grimfors G, Kanter-Lewensohn L, Linder O, Luthman M, Lofvenberg E, Nilsson-Ehle H, Samuelsson J, Tangen J, Winqvist I, Oberg G, Osterborg A, Ost A. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. American Society of Hematology. 1998;92(11):68-75.

Hellström-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl I, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Öberg G, Porwit-MacDonald A, Rådlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology. 2003;120:1037-46.

Henke M, Guttenberger R, Barke A, Pajonk F, Potter R, Frömmhold H. Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiotherapy and Oncology. 1999;50:185-90.

Henke M, Lazig R, Rube C, Schafer U, Haase K, Schilcher B, Mose S, Beer K, Burger U, Dougherty C, Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-60.




Henry D, Abels R. Prediction of response to recombinant human erythropoietin therapy in cancer patients. 1994; 21(2 Supp 3):21-8.

Henry D, Brooks B, Case D, Fishkin E, Jacobson R, Keller A, Kugler J, Moore J, Silver R, Storniolo A, Abels R, Gordon D, Nelson R, Larholt K, Bryant E, Rudnick S. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. The Cancer Journal from Scientific American. 1995; April:252-60.

Henry D, Patel R, Tchekmedyian S, Jumbe N, Austin M, Berg R, Allen C, Glaspy J. A phase 2 randomized study evaluating the timing of darbepoetin alfa administration relative to chemotherapy. Proc Am Soc Clin Oncol. 2003;22:3162.

Henry DH, Kamin M, Wilhelm F, Williams D, Xie J, Woodman RJ. Final results of a randomized study comparing two dosing regimens of epoetin alfa in patients with chemotherapy-induced anemia: 80,000 U every two weeks vs 40,000 U weekly. Journal of Clinical Oncology. 2006;24(18S):8624.

Henze G, Michon J, Morland B, Perek D, Rizzazi C, Zoubek A. Phase III randomized study: efficacy of epoetin alfa in reducing blood transfusions in newly diagnosed pediatric cancer patients receiving chemotherapy. Proc Am Soc Clin Oncol. 2002;21:1547.



Herrmann F, Mertelsmann R, Lindemann A, Ottman OG, Seipelt G, Oster W, Hoelzer D, Ganser A. Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndrome. Biotechnology Therapeutics. 1991;2(3&4):299-311.

Herrington J, Davidson S, Tomita D, Green L, Smith R, Boccia R. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am J Health Syst Pharm. 2005;62(1):54-62.

Hesketh PJ, Arena F, Patel D, Poulsen E, D'Avirro P, Rossi G, Schwartzberg L. Front-loaded darbepoetin alfa with Q3W maintenance administered as a fixed or weight-based dose in anemic cancer patients results in similar efficacy profiles. Proc Am Soc Clin Oncol. 2003;22:2941.

Hesketh J, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L. A Randomized controlled trial of Darbepoetin Alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. American Cancer Society. 2004;100(4):859-68.

Hirashima K, Bessho M, Jinnai I. Improvement in anemia by recombinant human erythropoietin in patients with myelodysplastic syndrome and aplastic anemia. Contributions to Nephrology. 1991;88:254-65.

Hitomi K, Fujita K, Sasaki R, Chiba H, Okuno Y, Ichiba S, Takahashi T, Imura H. Erythropoietin receptor of a human leukemic cell line with erythroid characteristics. Biochemical and Biophysical Research Communications. 1988;154(3):902-9.


Hoefsloot LH, van Amelsvoort MP, Broeders L, van der Plas DC, van Lom K, Hoogerbrugge H, Touw IP, L öwenberg B. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood. 1997;89(5):1690-1700.

Homoncik M, Jilma-Stohlawetz P, Schmid M, Ferlitsch A, Peck-Radosavljevic M. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2004;20(4):437-43.

Horiguchi H, Kayama F, Oguma E, Willmore W, Hradecky P, Bunn HF. Cadmium and platinum suppression of erythropoietin production in cell culture: Clinical implications. Blood. 2000;96:3743-7.

Hoshino S, Teramura M, Takahashi M, Motoji T, Oshimi K, Ueda M, Mizoguchi H. Expression and characterization of erythropoietin receptor s on normal human bone marrow cells. International Journal of Cell Cloning. 1989;7:156-7.

Huddart R, Welch R, Chan S, Perren T, Atkinson R. A prospective, randomised trial comparative-group evaluation of epoetin alfa for the treatment of anaemia in UK in cancer patients receiving platinum-based chemotherapy. Annals of Oncology. 2002;23:177.



Imamura M, Kobayashi M, Kobayashi S, Yoshida K, Mikuni C, Ishikawa Y, Matsumoto S, Sakamaki S, Niitsu Y, Hinoda Y, Yachi A, Kudoh T, Chiba S, Kasai M, Oka T, Okuno A, Maekawa I, Sakurada K, Miyazaki T. Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodsyplastic syndromes. Annals of Hematology. 1994;68:163-6.


Imamura M, Kobayashi M, Kobayashi S, Yoshida K, Mikuni C, Ishikawa Y, Matsumoto S, Sakamaki S, Niitsu Y, Hinoda Y, Yachi A, Kudoh T, Chiba S, Kasai M, Oka T, Okuno A, Maekawa I, Sakurada K, Miyazaki T. Combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in aplastic anemia. American Journal of Hematology. 1995;48:29-33.

Iniesta CB, Carpeño JD, Saenz EC, Batlle JF, Bernabeu F, Alves J, Cejas P, Sereno M, Perona R, Baron MG. Erythropoietin receptor expression in bladder cancer. Journal of Clinical Oncology. 2006;24(18S):4584.

Inomata Y, Hirata A, Takahashi E, Kawaji T, Fukushima M, Tanihara H. Elevated erythropoietin in vitreous with ischemic retinal diseases. Clinical Neuroscience and Neuropathology. 2004;15(5):877-9.

Isnard F, Najman A, Jaar B, Fenaux P, Baillou C, Khoury E, Labopin M, Laporte J, Woler M, Gorin N, Bauters F. Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes. Leukemia and Lymphoma. 1994;12:307-14.

Italian Cooperative Study Group. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. British Journal of Haematology. 1998;103:1070-74.



Printed on 3/10/2012. Page 127 of 201

Johansson J, Wersa P, Brandberg Y, Andersson S, Nordstrom L and the EPO-Study Group. Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate ancer: a randomized study. Scand J Urol Nephrol. 2001;35:288–94.


Jones S, D'Andrea A, Haines L, Wong G. Human erythropoietin receptor: cloning, expression, and biologic characterization. Blood. 1990;76:31–5.

Jumbe NL, Heatherington AC. Darbepoetin alfa rational dose/schedule evaluation based on quantitative understanding of erythropoiesis for early and sustained alleviation of anemia. Proc Am Soc Clin Oncol. 2003;22:abstract 3077.

Justice G, Kessler J, Jadeja J, Campos L, Weick J, Poulsen E, Jumbe N. Subcutaneous and intravenous darbepoetin alfa in patients with chemotherapy-induced anemia. Proc Am Soc Clin Oncol. 2003;22:3118.

Justice G. Kessler JF, Jadeja J, Campos L, Weick J, Chen CF, Heatherington AC, Amado RG. A randomized multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy –induce anemia. Annals of Oncology.2005;16:1192-1198.

Kagan A, Sinay-Trieman L, Bar-Khayim Y. Recombinant human erythropoietin for anaemia in thalassaemia minor patients on dialysis[Letter to the editor]. Nephrology Dialysis Transplantation. 1995;10(12):2375-6..



Kasselberg AG, Orth DN, Gray ME, Stahlman MT. Immunocytochemical localization of human epidermal growth factor/urogastrone in several human tissues. The Journal of Histochemistry and Cytochemistry. 1985;33(4):315-22.


Katodritou E, Speletas M, Zervas K, Kapetanos D, Georgiou E, Christoforidou A, Pavlitou A, Sion M, Christakis J. Evaluation of hypochromic erythrocytes in combination with s TfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma. Laboratory Hematology. 2006;12:47-54.


Kaufman S, Reda J, Fye C, Goldfarb D, Henderson W, Kleinman J, Vamone C. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med. 1998;339:578-83.

Kessler C. Anticoagulation and thrombolytic therapy. Practical considerations. Chest. 1989;95(5 Suppl):245S-56S.

Kirito K, Nakajima K, Watanabe T, Uchida M, Tanaka M, Ozawa K, Komatsu N. Identification of the human erythropoietin receptor region for Stat1 and Stat3 activation. Blood, 1 January 2002, Vol. 99, No. 1, pp. 102-110.


Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006 May 11;354(19):2079-80.





Koury S, Bondurant M, Koury M, Semenza G. Localization of cells producing erythropoietin in

murine liver by in situ hybridization. Blood. 1991;77:2497-2503.



Printed on 3/10/2012. Page 133 of 201

Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clinical Cancer Research. 2006;12:4283-7.

LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX, Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther. 2006;5(2):347-55.


Lage J, Panizo C, Masdeu J, Rocha E. Cyclist's doping associated with cerebral sinus thrombosis. Neurology. 2002;58:665.


Lai S, Childs E, Xi S, Coppelli F, Gooding W, Well A, Ferris R, Grandis J. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene. 2005;24:4442–9.

Lai SY, Lui VW, Koppikar J, Thomas SM, Gooding WE, Seethala RR, Bransletter BF, Argiris A, Grandis JR. Intratumoral Epidermal Growth Factor Receptor (EGFR) Antisense (AS) DNA in recurrent squamous cell carcinoma (SCCHN) of the head and neck: A phase 1 trial. Journal of Clinical Oncology. 2007; 25:1-2.

Laporte JPH, Isnard F, Fenaux P, Woler M, Najman A. Recombinant human erythropoietin at high dose is effective for the treatment of the anemia of myelodysplastic syndromes. Contributions to Nephrology. 1991;88:271-2; discussion 273-5.


Lappin T. The cellular biology of erythropoietin receptors. Oncologist. 2003;8 (Suppl 1):15-8.
Lappin T, Maxwell AP, Johnson PG. Warning flags for erythropoiesis-stimulation agents and cancer-associated anemia. The Oncologist. 2007;12:362-5.
Laupacis A. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. COPES Study Group.Lancet. 1993;342:378.
Lavey R, Dempsey W. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. International Journal of Radiation Oncology. 1993;27(5):1147-52.
Lavey R. Clinical trial experience using erythropoietin during radiation therapy. Strahlentherapie und Onkologie. 1998;174(Suppl IV):24-30.
Lavey R, Liub P, Greerc B, Robinson W IIId, Change P, Wynnf R, Conradg M, Jiangb C, Markmanh M, Albertsi D. Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB–IVA carcinoma of the cervix: a Southwest Oncology Group study. Gynecologic Oncology. 2004;95:145-51.
Lee A, Levine M. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost. 1999;25:137-45.








Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. 2005;23:5960-72. Epub 2005 Aug 8.

Libretto S, Barrett-Lee P, Branson K, Gorst D, Kaczmarski R, McAdam K, Stevenson P, Thomas R. Improvement in quality of life for cancer patients treated with epoetin alfa. European Journal of Cancer. 2001;10:183-91.









Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Treatment of anemia associated with multiple myeloma[Letter to the editor]. The New England Journal of Medicine. 1991;324(1):62-3.


Ludwig H, Leitgeb C, Fritz E, Krainer M, Kuhrer I, Kornek G, Sagaster P, Weibmann A. Erythropoietin treatment of chronic anaemia of cancer. European Journal of Cancer. 1993;29A(Suppl 2):S8-S12.

Ludwig H, Fritz E, Leitgeb C, Krainer M, Kuhrer I, Sagaster P, Umek H. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Annals Oncology. 1993;4:161-7.


Ludwig H, Pecherstorfer M, Leitgeb C, Fritz E. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. Stem Cells. 1993;11:348-55.

Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994;84(4):1056-63.

Ludwig H, Chott A, Fritz E, Krainer M. Increase of bone marrow cellularity during erythropoietin treatment in myeloma. Stem Cells. 1995; 13(suppl 2):77-87.



Macdougall IC. Poor response to erythropoietin. British Medical Journal. 1995;310:1424-5. Printed on 3/10/2012. Page 142 of 201



MacDougall I. Optimizing the use of erythropoietic agents—pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant. 2002;17(Suppl 5):66-70.

MacDougall J, Bailon P, Tare N. CERA (Continuous Erythropoiesis Receptor Activator) for the treatment of renal anemia: an innovative agent with unique receptor binding characteristics and prolonged serum half-life. J Am Soc Nephrol. 2003;14:769A.

MacDougall I. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005;4:436-40.

MacLennan S, Williamson LM. Risks of fresh frozen plasma and platelets. The Journal of Trauma Injury, Infection, and Critical Care. 2006;50(6):S46-50.

Machtay M, Pajak T, Suntharalingam M, Hershock D, Stripp D, Cmelak. Definitive radiotherapy +/- erythropoietin for squamous cell carcinoma of the head and neck: Preliminary report of RTOG 99-03. Int J Rad Oncol Biol Physics. 2004;60(Suppl 1):S132. RTOG 99-03 website. www.rtog.org/members/protocols/99-03/9903. www.rtog.org/members/protocols/99-03/revision. Accessed 3/20/97.



Malyszko J, Malyszko J, Pawlak K, Mysliwiec M. Erythropoietin and uremic platelet aggregation in vivo and in vitro. Int J Clin Lab Res. 1996;26:199-202.


Mannone L, Gardin C, Quarre MC, Bernard JF, Giraudier S, et al. High response rate to darbepoetin alfa in "low risk" results of a phase II study. Blood. 2004;104:abstract 69.

Mannone L, Gardin C, Quarre MC, Bernard JF, Vassilieff D, Ades L, Park S, Vaultier S, Hamza F, Beyne-rauzy MO, Cheze S, Giraudier S, Agape P, Legros L, Voillat L, Dreyfus F, Fenaux P. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. British Journal of Haematology. 2006;133:513-19.

Mantovani L, Lentini G, Hentschel B, Wickramanayake P, Loeffler M, Diehl V, Tesch H. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. British Journal of Haematology. 2000;109:367-75.

Marinaccio M, Mele E, Giotta F, Cantinieri C, Cocca M. Pretreatment normalization of mild anemia with epoetin alfa: impact on the outcome in epithelial ovarian cancer patients. Proc Am Soc Clin Oncol. 2003;22:1952.

Marinaccio M, Mele E, Poma S, Cantinieri C, Cocca M, Latiano T. Pretreatment normalization of mild anemia with epoetin alfa predicts long-term outcome for women with epithelial ovarian cancer. Journal of Clinical Oncology. 2004;22(14S):5132.



Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F Jr, Tabira T, Sasaki R. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem. 1993;268:11208-16.


Matsuda A, Kishimoto K, Yoshida K, Yagasaki F, Ito Y, Sakata T, Kawai N, Ino H, Hirashima K, Bessho M. Long-term follow-up of patients with aplastic anemia and refractory anemia responding to combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin. International Journal of Hematology. 2002;76:244-50.


Matsuda K, Idezawa T, You XJ, Kothari NH, Fan H, Korc M. Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. Cancer Research. 2002;62:5611-7.


Maurer AB, Ganser A, Seipelt G, Ottmann OG, Mentzel U, Geissler GR, Hoelzer D. Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors. British Journal of Haematology. 1995;89(3):449-51..

McKenzie RS. Use of erythropoietic agents in anemic lung cancer patients receiving chemotherapy. Proc Am Soc Clin Oncol. 2003;22:3145.

McMahon F, Vargas R, Ryan M, Jain A, Abels R, Perry B, Smith I. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood. 1990;76:1718-22.








Mittelman M, Zeidman A, Fradin Z, Magazanik A, Lewinski UH, Cohen A. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematologica. 1997;98:204-10.


Mittelman M, Zeidman A, Kanter P, Katz O, Oster H, Rund D, Neumann D. Erythropoietin has an anti-myeloma effect-a hypothesis based on a clinical observation supported by animal studies. European Journal of Haematology. 2004;72:155-65.

Moebus V, Bastert G, Kreienberg R, Eidtmann H, Cierna M, Untch M, Jackish C, Kliniken S. Epoetin alpha prevents anemia and transfusions of Rbcs in patients (pts) receiving dosedense sequential chemotherapy. Proc Am Soc Clin Oncol. 2001;20:abstract 36.

Moebus VJ, Untch M, DuBois A, Lueck HJ, Thomssen C, Kuhn W, Kurbacher C, Nitz U, Kreienberg R, Jackisch C. Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥4+LN). First results of an AGO-trial. Journal of Clinical Oncology. 2004;22(14S):513.

Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitmeir RJ, Rubin J, et al. Therapy of locally unrespectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high-dose radiation + 5-fluorouracil: the gastrointestinal tumor study group. Cancer. 1981;48(8):1705-10.





Munker R, Hasenclever D, Brosteanu O, Hiller E, Diehl V. Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1995;13:403-9.

Muñoz-Langa J, Juan O, Olmos S, Albert A, Molins C, Caranana V, Almenar D, Campos JM, Bosch C, Alberola V. Once-weekly dosing of epoetin alfa are similar to three-times-weekly dosing to improve hemoglobin levels in chemotherapy patients: results from multicenter prospective cohort study. Journal of Clinical Oncology. 2005;23(16S):8161.

Murphy L, Cluck MW, Lovas S, Otvos F, Murphy R, Schally AV, Permert J, Larsson J, Knezetic JA, Adrian TE. Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. British Journal of Cancer. 2001;84(7):926-35.

Murphy M, Wallington T, Kelsey P, Boulton F, Bruce M, Cohen H, Duguid J, Knowles S, Poole G, Williamson L, British Committee for Standards in Hematology. Guidelines for the clinical use of red cell transfusions. British Journal of Haematology. 2001;113:24–31.

Musto P, Falcone A, Carotenuto M. Granulocyte Colony-Stimulating Factor and Erythropoietin for the Anemia of Myelodysplastic Syndromes: A Real Improvement With Respect to Erythropoietin Alone? Blood. 1994;84(5):1687-8.

Musto P, Matera R, Minervini MM, Checchia-de Ambrosio C, Bodenizza C, Falcone A, Carotenuto M. Low serum levels of tumor necrosis factor and interleukin-1 ß in myelodysplastic syndromes responsive to recombinant erythropoietin. Haematologica. 1994;79:265-8.


Musto P, Modoni S, Alicino G, Savino A, Longo A, Bodenizza C, Falcone A, D'Arena G, Scalzulli P, Perla G, Casparrini G, and Carotenuto M. Modifications of Erythropoiesis in Myelodysplastic Syndromes Treated With Recombinant Erythropoietin As Evaluated By Soluble Transferrin Receptor, High Fluorescence Reticulocytes and Hypochromic Erythrocytes. Haematologica. 1994; 79;493-9.

Musto P, Scalzulli P, Carotenuto M. Recombinant Erythropoitin for Myelodysplastic Syndromes. British Journal of Haematology. 1995;91:256-7.

Musto P, Falcone A, D'Arena G, Scalzulli PR, Matera R, Minervini MM, Lombardi GF, Modoni S, Longo A, Carotenuto M. Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis. European Journal of Haematology. 1997;58:314-319.

Musto P, Sanpaolo G, D'Arena G, Scalzulli R, Matera R, Galcone A, Bodenizza C, Perla G, and Carotenuto M. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with meylodysplastic syndromes unresponsive to erythropoietin alone. Haematologica. 2001;86:44-51.

Musto P, Falcone A, Sanpaolo G, Bodenizza C, LaSala A, Perla G, Carella AM. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. British Journal of Haematology. 2003;122:269-71.




Musto P, Falcone A, Sanpaolo G, Bodenizza C. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes. Leukemia Research. 2006;30:385-8.


Mystakidou K, Kalaidopoulou O, Katsouda E, Parpa E, Kouskouni E, Chondros C, Tsiastas ML, Vlahos L. Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment. Anticancer Research. 2005;25:3495-3500.

Nakamura Y, Komatsu N, Nakauchi H. A truncated erythropoietin receptor that fails to prevent programmed cell death of erythroid cells. Science. 1992;257:1138-41.

Nakamura N, Chin H, Miyasaka N, Muira O. An Epidermal Growth factor Receptor/Jak2 Tyrosine Kinase Domain Chimera Induces Tyrosine Phosphorylation of Stat5 and Transduces a growth Signal in Hematopoietic Cells. The Journal of Biological Chemistry. 2001;271:19483-19488.

Narhi L, Arakawa T, Aoki K, Elmore R, Rohde M, Boone T, Strickland T. The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem. 1991;266:23022-6.





Negrin R, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg P. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood. 1996;87(10):4076-81.


Nestel P, Davidsson L. Anemia, iron deficiency, and iron deficiency anemia. Reviewed by INACG Steering Committee. 2002.


Neumeister P, Jaeger G, Eibl M, Sormann S, Zinke W, Linkesch W. Amifostine in Combination with erythropoietin and G-CSF promotes multilineage hematopoiesis in patients with myelodysplastic syndrome. Leukemia and Lymphoma. 2001;40:345-9.


New York Times – Business Section. Sec asks Amgen about anemia drugs. 3/1/07. Accessed 3/2/07.

Nilsson KR, Berenholtz SM, Garrett-Mayer E, Dorman T, Klag MJ, Pronovost PJ. Association between venous thromboembolism and perioperative allogeneic transfusion. Arch Surg. 2007;142:126-32.

Norda R, Tynell E, Åkerblom O. Cumulative risks of early fresh frozen plasma, cryoprecipitate and platelet transfusion in Europe. The Journal of Trauma Injury, Infection, and Critical Care. 2006;60(6):S41-45.







Österborg A, Boogaerts M, Cimino R, Essers U, Holowiecki J, Juliusson G, Jäger G, Najman A, Peest D for the European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-hodgkin's lymphoma – a randomized multicenter study. Blood. 1996;87:2675-82.


Österborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D for the Epoetin Beta Hematology Study Group. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol. 2002;20:2486-94.


Österborg A, Brandberg Y, Hedenus M. Impact of epoetin-β on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. British Journal of Haematology. 2005;129:206-9.

Österborg AC, De Boer R, Clemens M, Renczes G, Kotasek D, Prausova J, Marschner N, Hedenus M, Hendricks L, Amado R. A novel erythropoiesis-stimulating agent (AMG114) with 131-hour half-life effectively treats chemotherapy-induced anemia when administered as 200 mcg every 3 weeks. Journal of Clinical Oncology. 2006;24(18S):8626.

Österborg A, Steegmann J, Hellmann A, Couban S, Mayer J, Eid J. Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy. British Journal of Haematology. 2007;136:736-44.

Österborg A, Aapro M, Cornes P, Haselbeck A, Hayward CRW, Jelkmann W. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. European Journal of Cancer. 2007;43:510-9.





Patton JF, Sullivan T, Mun Y, Reeves T, Rossi G, Wallace JF. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome. Support Oncology. 2005;3(6):419-26.


Perillo A, Pierelli L, Scambia G, Serafini R, Paladini U, Salerno M, Bonanno G, Fattorossi A, Leone G, Mancuso S, Menichella G. Peripheral blood progenitor cell collection after epirubicin, paclitaxel, and cisplatin combination chemotherapy using EPO-based cytokine regimens: a randomized comparison of G-CSF and sequential GM-/G-CSF. Transfusion. 2001;41:674-80.

Perillo A, Ferrandina G, Pierelli L, Rutella S, Mancuso S, Scambia G. Cytokines alone for PBPC collection in patients with advanced gynecological malignancies: G-CSF vs G-CSF plus EPO. Bone Marrow Transplantation. 2004;34:743-44.

Peterson M, Mao Q, Schwartzberg LS, Fortner BV. Higher rates of early response needed with epoetin alpha (epo) and darbepoetin alpha in the community setting. Proc Am Soc Clin Oncol. 2003;22:3149.

Petti MC, Aloe-Spiriti MA, Latagliata R, Bertelletti DS, Jazlouk G, De Filice L, Valentini T, Villa RS, Mandelli F. Treatment of Myelodysplastic Syndromes (MDS) With Recombinant Human Erythropoietin (rHuEPO): Preliminary Clinical Results reported at the Second International Conference on Myelodysplastic Syndromes. April 90 to March 91, Page 33.

Phillips T, Li Y, Kim K, McBride WH, Pajonk F. Erythropoietin affects the number of CD24-/low/CD44+ breast cancer initiating cells. American Association for Cancer Research. 2007;Los Angeles: April14-18.




Pierelli L, Menichella G, Scambia G, Teofili L, Iovino S, Serafini R, Panici P, Salerno G, Rumi C, Zini G, d'Onofrio G, Leone G, Mancuso S, Bizzi B. In vitro and in vivo effects of recombinant human erythropoietin plus recombinant human G-CSF on human haemopoietic progenitor cells. Bone Marrow Transplantation. 1994;14:23-30.


Pineo G, Regoeczi E, Hatton M, Brian M. The activation of coagulation by extracts of mucus: a possible pathway of intravascular coagulation accompanying adenocarcinomas. J Lab Clin Med. 1973;82:255-66.

Pirisi M, Fabris C, Soardo G, Cecchin E, Toniutto P, Bartoli E. Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment. J Hepatol. 1994;21:376–80.

Pirker R, Vansteenkiste J, Gately J, Yates P, Colowick A, Musil J. A Phase 3, Double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer. Proc Am Soc Clin Oncol. 2001;20:1572.

Platanias L, Miller C, Mick R, Hart R, Ozer H, McEvilly J, Jones R, Ratain M. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol. 1991;9:2021-26.





Quirt I, Robeson C, Lau C. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol. 2001;19:4126–34.

Quirt I, Kovacs M, Couture F, Turner A, Noble M, Burkes R, Dolan S, Plante R, Lau C, Chang J, Camacho F. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience. The Oncologist. 2006;11:73-82.

Rafanelli D, Grossi A, Longo G, Vannucchi AM, Bacci P, Ferrini PR. Recombinant human erythropoietin for treatment of myelodysplastic syndromes. Leukemia. 1992;6:323-7.

Ramakrishnan R, Cheung W, Wacholtz M, Minton N, Jusko W. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2004;44:991-1002.

Rankin E, Biju M, Liu Q, Unger T, Rha J, Johnson R, Simon M, Keith B, Haase V. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 2007;117:1068-77.

Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma[Letter to the editor]. New England Journal of Medicine. 2006;354(19):2079-80.

Razzano M, Caslini C, Cortelazzo S, Battistel V, Rambaldi A, Barbui T. Therapy With Human Recombinant Erythropoietin in Patients With Myelodysplastic Syndromes. British Journal of Haematology. 1992;81:628-30.


Razzano M, Caslini C, Cortelasso S, Battistel V, Rambaldi A, and Barbui T. Clinical and Biological Effects of Erythropoietin treatment of Myelodysplastic Syndrome. Leukemia and Lymphoma. 1993;10:127-34.

Razzouk BI, Hockenberry M, Hinds PS, Rackoff W, Hord JD. A double-blind, placebo-controlled study of once-weekly epoetin alfa in children with cancer undergoing myelosuppressive chemotherapy. Journal of Clinical Oncology. 2004;22(14S):8527.

Razzouk B, Hord J, Hockenberry M, Hinds P, Feusner J, Williams D, Rackoff W. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol. 2006;24:3583-89.

Rearden TP, Charu V, Saidman B, Ben-Jacob A, Justice GR. Results of a randomized study of every three-week dosing (Q3W) of chemotherapy-induced anemia (CIA). Journal of Clinical Oncology. 2004;22(14S):8064.

Reed W, Hussey D, DeGowin R. Implications of anemia of chronic disorders in patients anticipating radiotherapy. Am J Med Sci. 1994;308:9-15. Erratum in Am J Med Sci. 1994;308:288.



Reinhardt U, Tulusan A, Angermund R, Lutz H. Increased Hemoglobin Levels and Improved Quality—of-Life Assessments During Epoetin Alfa treatment in Anemic Cancer Patients: Results of a prospective, Multicenter German Trial. The Oncologist .2005; 10:225-237.


Rella C, Coviello M, Giotta F, Maiello E, Colavito P, Colangelo D, Quarenta M, Colucci G, Schittulli F. A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat. 1996;40:151-9.

Remacha AF, Arrizabalaga B, Villegas A, Mantiega R, Calvo T, Juliá A, Fuertes M, González FA, Font L, Juncá J, Del Arco A, Malcorra JJ, Equiza EP, Pérez de Mendiguren B, Romero M. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. Haematologica. 1999;84:1058-64.

Remacha AF, Nomdedéu JF, Puget G, Estivilli C, Sarda MP, Canals C, Aventin A. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic myeloproliferative disease, unclassifiable refractory anemia with ringed sideroblasts associated with marked thrombocytosis. The Hematology Journal. 2006,91:719-20.

Reuters. ImClone soars after setback to rival Amgen drug. March 23, 2007.

Ribatti D. A potential role of Leukemia. 2002;16:1890-1.
Ribati D, Polimeno G, Vacca A Marzollo A, Crivellato E, Nico B, Lucarelli G, Dammacco F. Correlation of bone marrow angiogenesis and mast cells with tryptase in myelodysplastic syndromes. Leukemia2002;16:1680-1684.
Ribatti D, Marzullo A, Nico B, Crivellato E, Ria R, Vacca A. Erythropoietin as an angiogenio factor in gastric carcinoma. Histopathology. 2003;42:246–50.
A-Ribatti D, Poliani P, Longo V, Mangieri D, Nico B, Vacca A. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology. 2007;50:636-41.
B-Ribatti D, Marzullo A, Gentilli A, Longo V, Nico B, Vacca A, Dammacco F. Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology. 2007;50:591-6.
Richards S, Gibbs RA. A truncated erythropoietin receptor and cell death: a reanalysis. Science. 1994;264:588-9.
Rickles F, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001;102:V215-24.





pressure in experimental hypertension and uraemia without change in vascular cytosolic


Printed on 3/10/2012. Page 170 of 201

calcium. Nephron.1996;73:212-8.


























Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovascular Research. 2003;59:538-48.

Smith Jr R, Tchekmedyian N, Chan D, Meza L, Northfelt D, Patel R, Austin M, Colowick A, Rossi G, Glaspy J for the Aranesp 990111 Study Group. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. British Journal of Cancer. 2003;88;1851-58.


Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer. 2000;89(2):314-27.

Spiridonidis H, Brinkmann K, Gore K, Tannous RE, Gupta S. Evaluating the "effectiveness" of epoetin alfa in oncology. Proc Am Soc Clin Oncol. 2002;21:1482.

Spiriti MA, Latagliata R, Niscola P, Cortelezzi A, Francesconi M, Ferrari D, Volpe E, Clavio M, Grossi A, Reyes MT, Musto P, Mitra ME, Azzará A, Pagnini D, D'Arena G, Spadano A, Balleari E, Pecorari P, Capochiani E, De Biasi E, Perego D, Monarca B, Pisani F, Scaramella G, Petti MC. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Annals of Hematology. 2005;84:167-76.



Printed on 3/10/2012. Page 181 of 201




Stasi R, Abruzzese E, Lanzetta G, Terzoli E, Amadori S. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Annals of Oncology. 2005;16:1921-27.


Stasi R, Amadori S, Littlewood TJ, Terzoli E, Newland AC, Provan D. Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns. The Oncologist. 2005;10:539-54.

Stebler C, Tichelli A, Dazzi H, Gratwohl A, Nissen C, Speck B. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study. Experimental Hematology. 1990;18:1204-8.

Steensma D, Witzig TE. Does treatment with recombinant human erythropoietin affect the survival of anemic patients with cancer? (commentary). Nature Clinical Practice Oncology. 2005;2(9):444-5.

Steensma D, Molina R, Sloan J, Nikecevich D, Schaefer P, Rowland Jr, K, Dentchev T, Novotny P, Tschetter L, Alberts S, Hogan T, Law A, Loprinzi C. Phase III Study of Two Different Dosing Schedules of Erythropoietin in Anemic Patients with Cancer. Journal of Clinical Oncology. 2006; 24: 1079-1089.





Printed on 3/10/2012. Page 184 of 201

Medicine, 2003:1-33.

Sweeney P, Nicolae D, Ignacio L, Chen L, Roach III M, Wara W, Marcus K, Vijayakumar S. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labeled, phase II trial. British Journal of Cancer. 1998;77:1996-2002.

Sytkowski A, Feldman L, Zurbuch D. Biological activity and structural stability of N-deglycosylated recombinant human erythropoietin. Biochem Biophys Res Commun. 1991;176:698-704.

Takeshita A, Shinjo K, Higuchi M, Miyawaki S, et al. Quantitative expression of erythropoietin receptor (EPO-R) on acute leukaemia cells: relationships between the amount of EPO-R and CD phenotypes, in vitro proliferative response, the amount of other cytokine receptors and clinical programs. British Journal of Haematology. 2000;108:55-63.

Takeshita A, Shinjo K, Naito K, Ohnishi K, Higuchi M, Ohno R. Erythopoietin receptor in myelodysplastic syndromes and leukemia. Leukemia & Lymphoma. 2002;43(2):261-4.

Tam B, Wei K, Rudge J, Hoffman J, Holash J, Park S, Yuan J, Hefner C, Chartier C, Lee J, Jiang S, Niyak N, Kuypers F, Ma L, Sundram U, Wu G, Garcia J, Schrier S, Maher J, Johnson R, Yancopoulos G, Mulligan R, Kuo C. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med. 200612:793-800. Epub 2006 Jun 25.

Tarabay G, Braly P, Baker JJ, Williams D, Waltzman RJ. Treatment of anemia with epoetin alfa 80,000 U QW in cancer patients receiving chemotherapy. Journal of Clinical Oncology. 2004;22(14S):8205.

Tarantolo S, Bouda DW. Early results from a novel treatment strategy for chemotherapy-related anemia: epoetin alfa 60,000 U SC QW induction followed by 60,000 U SC Q2W. Journal of Clinical Oncology. 2004;22(14S):8204.

Tas F, Eralp Y, Basaran M, Sakar B, Alici S, Argon A, Bulutiar G, Camlica H, Aydiner A, Topuz E. Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol. 2002;25:371-9.

Taylor J, McLaren M, Henderson I, Belch J, Stewart W. Prothrombotic effect of erythropoietin in dialysis patients. Nephrol Dial Transplant. 1992;7:235–9.

Taylor D, Yoka B, Kusumanto H, Meijer C, Mulder NH, Hospers G. A review on pro-and-antioangiogenic factors as targets of clinical intervention. Pharmacol Res. 2006;53(2):89-103.

Ten Bokkel Huinink WW, de Swart C, van Toom D, Morack G, Breed W, Hillen H, van der Hoeven J, Reed N, Fairlamb D, Chan S, Godfrey K, Kristensen G, van Tinteren H, Ehmer B. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Medical Oncology. 1998;15:174-82.

Terpos E, Mougiou A, Kouraklis A, Chatzivassili A, Michalis E, Giannakoulas N, Manioudaki E, Lazaridou A, Bakaloudi V, Protopappa M, Liapi D, Grouzi E, Parharidou A, Symeonidis A, Kokkini G, Laoutaris NP, Vaipoulos G, Anagnostopoulos NI, Christakis JI, Meletis J, Bourantas KL, Zoumbos NC, Yataganas X, Viniou N. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. British Journal of Haematology. 2002;118:174-80.

Thames W, Yao B, Scheifele A, Alley JL. Drug use evaluation (DUE) of darbepoetin alfa in anemic patients undergoing chemotherapy supports a fixed dose of 200 mcg Q2W given every 2 weeks (Q2W). Proc Am Clin Oncol. 2003;22:2196.

Thatcher N, De Campos E, Bell D, Steward W, Varghese G, Morant R, Vansteenkiste J, Rosso R, Ewers S, Sundal E, Schatzmann E, Stocker H. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. British Journal of Cancer. 1999;80(3/4):396-402.

Thomas GM. Raising hemoglobin: an opportunity for increasing survival? Oncology. 2002;63(suppl 2):19-28.

Thomas H, McAdam K, Thomas R, Joffe J, Sugden E, Awwad S. Early intervention with epoetin alpha for treatment of anaemia and improvement of quality of life in cancer patients undergoing myelotoxic chemotherapy. Annals of Oncology. 2002;Vol 13 (Suppl 5):177#653P.

Thompson J, Gilliland D, Prchal J, Bennett J, Larholt K, Nelson R, Rose E, Dugan M, GM/EPO MDS Study Group. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood. 2000;95(4):1175-9.

Throuvalas N, Antonadou D, Boufi M, Lavey R, Malamos N. Erythropoietin decreases transfusion requirements during radiochemotherapy. Proc Am Soc Clin Oncol. 2000;19:1558.







Urabe A, Mizoguchi H, Takaka F, Miyazaki T, Yachi A, Niitsu Y, Miura Y, Mutoh Y, Fujioka S, Nomura T, Toyama K, Kawato M, Kurokawa K, Yazaki Y, Onozawa Y, Togawa A, Mori M, Enomoto H, Ogawa M, Ikeda Y, Ohshima T, Aoki I, Shionoya S, Arimori S, Chiba S, Omine M, Saito H, Ohno R, Kodera Y, Hirabayashi N, Nakagawa M, Kasuga M, Niho Y, Etoh S, Takatsuki K, Araki K. Phase II clinical study of recombinant human erythropoietin on the

anemia associated with multiple myeloma. Japan Society of Clinical Hematology.

1993;34(8):919-27.






Valera ET, Do Rosário Dias Latorre M, Mendes WL, Seber A, De Martino Lee ML, De Paula MJA, Loggetto SR, Velloso E, Niero-Melo L, Lopes LF. Treatment of pediatric myelodysplastic syndromes and juvenile myelomonocytic leukemia: the Brazilian experience in the past decade. Leukemia Research. 2004;28:933-9.


Van den Bosch J, van de werf P, Sleeboom H, Biesma B, Kerkhofs L, Mol J, Ten Velde G, Melissant C. Improvements in anemia management with epoetin alfa-a dutch survey. Journal of Clinical Oncology. 2005;23(16S):8126.

Van der Niepen P, Sennesael J, Verbeelen D. r-HuEPO treatment of anemia associated with multiple myeloma and ESRD[Letter to the editor]. Clinical Nephrology. 1993;39(2):113.

Van Kamp H, Prinsze-Postema T, Kluin P, Den Ottolander G, Veverstock G, Willemze R, and Fibbe W. Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. British Journal of Haematology. 1991;78:488-93.

Vannucchi AM, Grossi A, Bosi A, Rafanelli D, Statello M, Guidi S, Saccardi R, Rossi-Ferrini P. Effects of cyclosporine A on erythropoietin production by the human Hep3B hepatoma cell line. Blood. 1993;82(3):978-84.






Vekeman F, McKenzie RS, Watson S, Mody S, Lefebvre P, Piech CT, Duh MS. Comparison of red blood cell transfusion rates of epoetin alfa and darbepoetin alfa in an inpatient oncology setting. Journal of Clinical Oncology. 2006;24(18S):16002.


Vercammen E, Ludwig H, Liu K, Xiu L, Bowers P. Analysis of the effect of body weight on the efficacy and safety of epoetin alfa. Journal of Clinical Oncology. 2005;23(16S):8184.

Verhoef G, Zachee P, Ferrant A, Demuynch H. Selleslag D, and Boogaerts M. Recombinant Human Erythropoietin for the Treatment of Anaemia in the Myelodysplastic Syndromes. Second International Conference on Myelodysplastic Syndromes.


Verhoef GEG, Zachee P, Ferrant A, Demuynck H, Sellaslag D, Van Hove L, Deckers F, Boogaerts MA. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment. Annals of Hematology. 1992;64:16-21.


Verhoef GE, Demuynck H, Zachee P, Boogaerts MA. Myelodysplastic syndrome evolving into a myeloproliferative disorder: one disease or two? [Letter to the editor]. Leukemia. 1994;8(4):714-715.







Printed on 3/10/2012. Page 195 of 201









Wun T, Law L, Harvey D, Sieracki B, Scudder S, Ryu J. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer. 2003;98:1514-20.

Wurnig C, Windhager R, Schwameis E, Kotz R, Zoubek A, Stockenhuber F, Kurz R. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (A double-blind, randomized, phase III study). Transfusion. 1996;36:155-59.

Xia K, Mukhopadhyay N, Inhorn R, Barber D, Rose P, Lee R, Narsimhan R, D'Andrea A, Griffin J, Roberts T. The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner. Proc Natl Acad Sci U S A. 1996;93:11681-6.

Yamada K, Murakami M, Okamoto Y, Okuno Y, Nakajima T, Kusumi F, Takakuwa H, Matsusue S. Treatment results of chemo-radiotherapy for clinical stage I (T1N0M0) esphogael carcinoma. I.J. Radiation Oncology Biology Physics. 2004;60(1):S300.

Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem. 1998;273:25381–7.

